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1.1. Classical lipid nanoparticles ᅳ SLN® and NLC® 
 
Following the development of liposomes and polymeric nanoparticles, solid lipid 
nanoparticles (SLN®) were invented at the beginning of the 1990’s for the delivery of 
active ingredients (Lucks and Müller, 1991). A major advantage of the solid lipid matrix is 
its ability to protect the incorporated active ingredients against chemical degradation, 
resulting in significantly enhanced shelf life. However, crystalline lattice structures within 
the SLN®  can lead to drug expulsion and lower drug loading capacities (Mehnert and 
Mäder, 2001; Müller et al., 2000). In order to tackle these drawbacks, the second 
generation of lipid nanoparticles – nanostructured lipid carriers (NLC®) – were developed 
in 2000. The lipid matrix of NLC® is composed of both a solid lipid and a certain amount 
of a liquid lipid (oil), creating imperfections in the crystal lattice, resulting in improved drug 
loading capacity as well as physical stability. 
 
The development of SLN® and NLC® formulations with uniform particle size distributions 
and good physical long-term stability requires careful optimization of the composition 
across a wide spectrum of stabilizers/surfactants. The type of surfactants used also 
influences the possible applications of SLN® and NLC® products. For example, in dermal 
delivery systems, the toxicity of the surfactant is an important consideration. Conventional 
nonionic polyhydroxy and polyglyceride surfactants exhibiting a good safety profile - for 
example Plantacare®, Sisterna®, Surfhope® and Plurol Stearique® - are widely used for 
the stabilization of lipid nanoparticles (von Rybinski and Hill, 1998). Furthermore, the type 
of surfactant used also influences the particle size and physical stability. The molecular 
structure of the surfactant also influences the particle size: surfactants with high 
hydrophilic-lipophilic balance (HLB) values and a lower molecular weight tend to form 
smaller particles (Kovačević et al., 2014). A relevant investigation of different alkyl 
polyglycosides (APGs) supports a similar conclusion, showing surfactants with shorter 
alkyl chains and higher critical micelle concentrations (CMC) lead to a reduced particle 
size (Keck et al., 2014). 
 





However, for each specific drug candidate loaded using SLN® or NLC® formulations, a 
tedious lipid screening procedure is inevitable. Usually, the development of such a system 
includes screening the miscibility, solubility and partition coefficients of the drug in various 
lipids, which is a time-consuming and resource-intensive process. Moreover, the drug 
loading capacity of the SLN® or NLC® system could be significantly higher than the 
solubility of the drug, further complicating the formulation development. A recent study 
(Göke and Bunjes, 2017) introduced a novel screening approach named passive drug 
loading, in which different lipid nanoparticles are incubated with the raw drug powder. 
After removing the undissolved drug by filtration, the exact amount of solubilized drug is 
determined. Furthermore, this approach can be used to determine the drug localization 
by relating the specific lipid nanoparticles’ surface area to the drug solubility. For SLN® 
and NLC®, three different models describe the localization of the active compound in the 
system: the homogeneous matrix model, drug-enriched shell model and drug-enriched 
core model. Formulation composition as well as production conditions provide a toolbox 
to target a specific drug localization in the lipid nanoparticle, and each type of drug 
localization brings about distinct release properties (Dingler et al., 1997; Müller et al., 
2002). The homogeneous matrix facilitates continuous release from 1 day up to weeks, 
whereas the drug-enriched shell model is suitable for dermal applications, enabling a very 
fast release as well as enhanced drug penetration. The drug-enriched core model leads 
to a passive membrane-controlled release. The identification of the drug localization not 
only reduces formulation development time, but also serves as a reference for 
development targeting a specific application. 
 
1.2. Lipid-drug-conjugate (LDC) 
 
A major drawback of SLN® and NLC® systems is the low loading capacity for hydrophilic 
drugs as a result of the partitioning effect. This is not a problem for highly potent actives 
such as follicle-stimulating hormone (FSH) and erythropoietin (EPO), but poses a serious 
limitation when higher dosages of hydrophilic drugs are required. In order to overcome 
this obstacle, lipid-drug-conjugate (LDC) systems were developed (Olbrich et al., 2002). 





water-insoluble molecule by either covalent linkage or by salt formation (Muchow et al., 
2008). The obtained LDC can be incorporated into lipid nanoparticle formulations either 
with or without other lipids using high-pressure homogenization production techniques. 
Such LDC nanoparticles demonstrate several advantages including improved oral 
bioavailability, enhanced tumor targeting and increased drug loading capacity into 
delivery carrier systems (Irby et al., 2017). 
 
Numerous drugs cannot be utilized for oral application directly, owing to low bioavailability. 
The first-pass effect as well as other metabolic restrictions limit the uptake of these drugs. 
Delivering drugs in LDC form avoids these barriers by following lipid metabolism 
pathways. The main function of the lymphatic system is transporting dietary lipids from 
the intestines to lymphatic capillaries. In this way, uptake of the drug is enhanced by the 
avoidance of the first-pass effect (Trevaskis et al., 2015). A further study demonstrated 
that conjugating cytarabine (1-β-D-arabinofuranosylcytosine, Ara-C) with lauric acid 
results in an almost 33-fold increase of cytarabine bioavailability by oral administration in 
rats (Liu et al., 2016).  LDC have also been used in conjugation with lipid nanoparticle 
systems, where the increased lipophilicity of the conjugate improves compatibility with the 
other components and reduces drug leakage (Li et al., 2016; Shao et al., 2013). One 
study showed a novel 2′-behenoyl-paclitaxel conjugate nanoparticle formulation for the 
treatment of breast cancer (Ma et al., 2013). The lipophilic paclitaxel derivative increased 
drug loading in lipid-based nanoparticles from 10% to 47%. Aside from increased drug 
loading and stability, LDC nanoparticles can also aid in the delivery of hydrophilic drugs. 
For example, LDC nanoparticles containing a conjugate of the hydrophilic drug 
diminazene diaceturate with stearic and oleic acid was developed for potential delivery to 
the brain (Olbrich et al., 2004). With a drug loading capacity of 33% (w/w), the LDC-based 
SLN® showed strong potential owing to the combination of increased loading with 
enhanced delivery. In addition, gene medicines such as siRNA are novel promising 
therapeutic agents which started attracting worldwide interest in recent years, but their 
poor stability and negative charge limits clinical application of siRNA agents (Petrova et 
al., 2011; Urbinati et al., 2016). As LDC can both stabilize as well as increase loading 





delivery. A recent study showed that conjugating siRNA to lipophilic palmitic acid 
increased the loading capacity in nanoparticle formulations (Sarett et al., 2015). This 
conjugation exhibited 35-fold increased intracellular uptake of the siRNA, and at the same 
time led to a 3.1-fold increase in intracellular half-life in comparison to unconjugated 
siRNA. Complexation with cationic lipids - such as DOPAP - also proves to be a useful 
strategy towards forming lipid nanoparticles for siRNA transfection (Lobovkina et al., 
2011).  
 
Medical applications of LDC in lipid nanoparticles have already been demonstrated, 
showing high drug loading as well as enhanced targeted drug delivery in vivo. LDC can 
be a promising delivery system in cancer therapy,  since many tumor cells are fenestrated, 
and thus can easily be penetrated by nanoparticles (Ferrari, 2005). In one study, the LDC 
stearoyl gemcitabine was loaded into lipid nanoparticles (GemC18-NPs) for solid tumor 
therapy (Chung et al., 2012). Combined with soy lecithin, glycerol monostearate and LDC, 
this lipid nanoparticle formulation was physically stable for 20 days. The results showed 




Recently, smartLipids® particles were developed as the new generation of lipid 
nanoparticles after SLN® and NLC®. The first generation, SLN®, are typically produced 
from one solid lipid, and the lipid matrix exists as a highly ordered crystalline structure. 
Because of this, SLN® show limitations in drug loading capacity, and drug expulsion can 
occur during storage. NLC®, the second generation of lipid nanoparticles, were developed 
with a mixture of typically a single solid lipid and a single liquid lipid. The addition of liquid 
lipid introduces imperfections in the lipid matrix, increasing the solubility of the actives 
and reducing drug expulsion. Following these iterative advancements, smartLipids® were 
developed in 2014 as the 3rd generation of lipid nanoparticles, consisting of a more 
complex lipid mixture (Müller et al., 2014). The particle matrix consists in most cases of 
more than five different lipids, containing mono-, di- and triglycerides with various carbon 





mixture provides increased drug loading and better protection for chemically labile 
molecules. 
  
Owing to the highly optimized matrix structure formed using various lipid molecules, 
polymorphic transitions during shelf life are minimized or even can be completely avoided 
(Ruick, 2016). This firm inclusion in the particle matrix is required to protect the loaded 
drug. As mentioned in 1.1, the development procedure for a new formulation based on 
classical lipid nanoparticle systems takes considerable effort and time, owing to the 
screening of numerous potential lipids. Consisting of multiple solid and liquid lipids, 
smartLipids® possess great potential to incorporate a variety of drugs, and thus the 
requirement of lipid screening procedures in conventional lipid nanoparticle formulation 
development can be minimized by pursuing this more universal approach. The complex 
lipid nanoparticle matrix has a low ordered crystallinity of solid lipids, increasing the 
amount of imperfections leading to higher drug loading capacity compared to classical 
SLN® and NLC® delivery system.  
 
As the 3rd generation of lipid nanoparticle systems, they inherit the advantages of SLN® 
and NLC® systems. These include a nano-range and narrow particle size distribution, 
prolonged release profile, minimizing side effects of the incorporated drug and the 
feasibility of scale-up to industrial production scales. In addition, lipid nanoparticles 
possess adhesive properties when applied to topical and mucosal surfaces (Liu et al., 
2011; Pyo et al., 2016). By adhesion to the skin, an occlusive film also protects the skin 
against exogenous hazards. Combining these advantages, smartLipids® show great 
potential for dermal application. In a previous work, smartLipids® with a physical stability 
of at least three months at room temperature were demonstrated (Junmahasathien, 2015). 
This formulation was further investigated by incorporating it into different dermal bases, 
such as a Poloxamer 407 hydrogel, cream and lotion (Li, 2016). Nowadays, smartLipids® 
products are already commercially available (e.g. BergaCare smartLipids® (Olechowski 






1.4. Lipid nanoparticles for dermal and mucosal application 
 
Lipid nanoparticles were first introduced into dermal delivery around 2000. In the past 10 
years, SLN® and NLC® have drawn much attention for dermal application and shown 
great advantages such as the good skin compatibility and skin penetration of drugs (Keck 
et al., 2007; Müller et al., 2011). Since adhesiveness increases with a decreasing particle 
size, the nano-sized particles are able to adhere strongly to surfaces. In addition, 
hydrophobic interactions further enhance the adhesiveness of lipid nanoparticles to the 
skin. The nanoparticles form a dense “invisible patch” onto the bare patches of the skin. 
This protective lipid film increases the skin hydration, reduces water loss, enhances 
penetration of actives and restores the living conditions for the skin cells (Keck and Müller, 
2010). Furthermore, the lipids making up the nanoparticles bear a resemblance to those 
making up the skin cell membranes, and show no toxicity (Pardeike et al., 2009). 
 
A review by Müller (Müller et al., 2011) already summarized numerous SLN®-based 
dermal investigations, but recently several new concepts emerged in this area. 
Chantaburanan et al. developed SLN® with solid complex triglycerides (Softisan 378) and 
solid wax (cetyl palmitate) in different ratios for ibuprofen delivery. All the SLN® 
formulations prepared from different ratios demonstrated an initial burst release followed 
by sustained release properties. The addition of Softisan 378 into a cetyl palmitate matrix 
led to slow ibuprofen release owing to the drug-lipid interaction when increasing the 
amount of Softisan 378, showing sustained release properties can be adjusted depending 
on the lipid ratio (Chantaburanan et al., 2017). Another group prepared a SLN®-based gel 
for the dermal delivery of meloxicam. The formulation was produced with cetyl palmitate, 
Tween® 80 and propylene glycol, and subsequently incorporated into a hydrogel using 
carbopol 940. The resulting formulation showed controlled release properties as well as 
the potential of transporting the drug to deeper skin layers, as evidenced by increased 
penetration of meloxicam into the skin of mice. Furthermore, this delivery system 
exhibited anti-inflammatory activity as well as good skin tolerability, proving to be an 
excellent method for the delivery of meloxicam (Khurana et al., 2013). Pyo introduced a 





study, vitamin K1 and A1 were incorporated into SLN®, and rutin was formulated as a 
nanocrystal. SLN® prolonged drug release and enhanced penetration in porcine ear skin, 
and the presence of rutin nanocrystals performed antioxidant activity. The in vivo study 
showed three to six times faster recovery by twice daily application of the new formulation 
compared to the raw drug as a micro-sized powder (Pyo et al., 2016). Lipid nanoparticles 
were also used for griseofulvin application. The formulation showed more than 5 folds 
penetration as well as a controlled drug release (Aggarwal and Goindi, 2013).   
 
Mucosa shares morphological similarities with skin, and thus transmucosal drug delivery 
is considered as a convenient, mild and safe method. In general, mucosal delivery routes 
include oral, buccal, ocular, intranasal and vaginal. Owing to their nanoscale size, lipid 
nanoparticles possess advantageous properties for mucosal application. Shah et al. 
investigated rivastigmine-loaded SLN® composed of Compritol 888 ATO, Tween® 80 and 
Poloxamer 188, using a Quality by Design (QbD) approach for intranasal delivery. By 
identifying the effect of independent variables (drug-to-lipid ratio, surfactant concentration 
and homogenization time), rivastigmine-loaded SLN® showed high in-vitro and ex-vivo 
diffusion. A histopathology study ensured the safety of rivastigmine-loaded SLN® for 
intranasal administration (Shah et al., 2015). 
 
However, the application of lipid nanoparticle into mucosa is limited by the protective 
mucus layer, which covers the epithelium and removes foreign particles (Wu et al., 2015). 
In order to overcome this, several strategies are pursued. One of the major methods is 
producing positively charged nanoparticles. Because the mucosa carries a negative 
charge, positively charged lipid nanoparticles can adhere strongly to mucosa. Thus, 
cetylpyridinium chloride (CPC) was used as positively charged ionic surfactant to form 
NLC®, and the resulting particles adhered excellently to the mucosa (Hommoss et al., 
2017; Müller et al., 2009). A further effective way to overcome this barrier is the so-called 
modification strategy, such as the production of targeting delivery vehicles. CSKSSDYQC 
(CSK) was found to be an effective peptide, exhibiting a strong goblet cell targeting 
property (Jin et al., 2012; Kang et al., 2008). Based on this, Fan et al. designed SLN® 





in order to improve cellular uptake of the drug. The result showed that the two modified 
SLN® formulations enhanced drug permeation in excised rat duodenum mucosa, and 
increased the drug bioavailability compared to conventional SLN® (Fan et al., 2014). In a 
further study, SLN® were successfully incorporated into mucoadhesive sponges for 
buccal delivery of curcumin (Hazzah et al., 2015).Curcumin was formulated as a SLN® 
system, and the prepared SLN® suspension was thickened using mucoadhesive 
polymers. The investigation showed a polycarbophil sponge provided a sustained release 
for 15 hours in the buccal cavity, exhibiting a steady release of curcumin, indicating a 
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The overarching aim of this thesis was developing lipid nanoparticle delivery systems –
solid lipid nanoparticles (SLN®) and smartLipids® – for various pharmaceutical actives. 
These systems should be able to offer significant advantages, such as increased drug 
loading capability and stability. This goal was subdivided into the following subtopics: 
 
Chapter 3:  Nicotine-loaded SLN® were to be developed for suppressing common side 
effects of conventional nicotine replacement therapy. The main aim was to maximize the 
encapsulation efficiency of the hydrophilic nicotine, and the strategy pursued involved 
incorporating lipid drug conjugates (LDC) of nicotine and fatty acids (stearic acid and 
Kolliwax® S) into SLN®. The formed delivery system should be compared to non-LDC 
SLN® formulations in order to identify key advantages. 
 
Chapter 4: The dermal application of retinol for anti-skin-aging treatment receives 
considerable interest, but retinol is susceptible to chemical oxidation. Thus, optimized 
smartLipids® formulations should be developed offering higher retinol stability. In addition 
to both chemical and physical stabilities, the possibility of increasing the retinol loading in 
the novel formulations should be investigated. Working towards practical application, the 
lipid nanoparticles should be incorporated into a dermal gel base and the stability should 
also be determined.  
 
Chapter 5: Although smartLipids® are highly promising based on their unique structure of 
the lipid matrix, their complex composition can make the development of stable 
formulations cumbersome. Therefore, the influence of relevant parameters - including 
lipid composition, surfactant, addition of oil and production parameters - on formulation 
stability should be investigated. 
 
Chapter 6: The powerful antioxidant α-tocopherol can protect the skin against UV-induced 
oxidative damage, but higher active loading is desirable. For cosmetic products, a 
concentrate with higher α-tocopherol content is needed. Therefore, the α-tocopherol 
SLN® formulations with increased loading should be developed, and the stability of the 
produced formulations should be investigated. 
Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN®) for the delivery of nicotine to the oral 
cavity – optimization of nicotine loading efficiency 
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3. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN®) 
for the delivery of nicotine to the oral cavity – optimization of 
nicotine loading efficiency  
 
https://doi.org/10.1016/j.ejpb.2018.03.004 (page 17-39) 
 
(Ding, Y., Nielsen, K. A., Nielsen, B. P., Bøje, N. W., Müller, R. H., Pyo, S. M., Lipid-drug-
conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral 
cavity–optimization of nicotine loading efficiency. European Journal of Pharmaceutics 
and Biopharmaceutics, 2018, 128: 10-17.)




4. smartLipids® as third solid lipid nanoparticle generation – 
stabilization of retinol for dermal application 
 
https://doi.org/10.1691/ph.2017.7016 (page 41-69) 
 
(Ding, Y., Pyo, S. M., Müller, R. H., smartLipids® as third solid lipid nanoparticle 
generation–stabilization of retinol for dermal application. Die Pharmazie-An International 
Journal of Pharmaceutical Sciences, 2017, 72(12): 728-735.)





5. The influencing factors of producing stable smartLipids®: 
lipids, surfactants and production parameters






smartLipids®, which consist of a complex combination of lipids, are used to improve the 
chemical stability and entrapment efficiency of poorly soluble active pharmaceutical 
ingredients (APIs). Although the possibility of increased loading for a wide variety of drugs 
makes a more universal delivery approach possible, mixing multiple lipids makes it 
challenging to develop smartLipids® formulations with long-time storage stability. Thus, 
the focus of this study is the development of stable smartLipids®, as well as in-depth 
investigation of the factors directly influencing physical stability properties. The physical 
stability was determined by monitoring particle size as well as size distribution by photon 
correlation spectroscopy (PCS) and laser diffractometry (LD) up to 180 days of storage. 
The smartLipids® formulations produced with four lipid combinations with different melting 
ranges, four stabilizing surfactants at two different concentrations, and various 
homogenization parameters were investigated. The results show that stable smartLipids® 
formulations can be achieved with low melting range lipid compositions, stabilized with 
surfactants having relative high hydrophilic-lipophilic balance (HLB) values, and 
performing one or two homogenization cycles. Furthermore, adding liquid lipid into the 
lipid matrix improves the physical stability of smartLipids®. In this work, a framework 
critical for the production of stable smartLipids® is outlined, which can be used for further 




Lipid nanoparticles – first generation: solid lipid nanoparticles (SLN®) (Lucks and Müller, 
1991) and second generation: nanostructured lipid carriers (NLC®) (Müller et al., 2002a) 
– are amongst the most promising formulation approaches for the delivery of lipid-soluble 
drugs. As an improvement on nanoemulsion, SLN® are composed of a solid rather than 
liquid lipid. Due to the solid matrix, this system is superior to nanoemulsions in terms of 
both chemical protection of actives, as well as occlusion behavior in order to increase 
biocompatibility and bioavailability (Müller et al., 2000). As the second generation of lipid 





nanoparticles, NLC® were developed in 2002 using typically a blend of one solid lipid and 
one liquid lipid. The addition of the liquid lipid (oil) distorts the ordered crystalline structure 
of SLN® and increases imperfections in the lipid matrix. In many cases, active 
pharmaceutical ingredients (APIs) present better solubility behavior in oil compared to 
solid lipid mixtures. Thus, the entrapment efficiency of NLC® was improved. A 
pharmaceutical or cosmetic delivery system should be able to have a sufficiently high 
drug loading, and keep the API chemically stable during the shelf life. For developing a 
new formulation based on classical lipid nanoparticle systems, the first step is lipid 
screening, meaning the measurement of solubility for the API in different lipids (Chen et 
al., 2012). However, the procedure of solubility screening in various lipids is a time and 
resource intensive process, since there are numerous potential lipids that need to be 
investigated. Additionally, not each lipid-drug combination showing promising loading 
capacity also provides long term stability, meaning numerous dead ends will inevitably be 
pursued. Recently, Bunjes’ research group developed a novel screening method named 
“passive drug loading”. After incubating different lipid nanocarrier dispersions with pure 
drug powder, the exact amount of loaded drug was measured. Using this method, the 
best formulation with the highest drug loading was determined (Göke and Bunjes, 2017). 
This method not only established an effective and rational way for drug solubility 
identification, but could also serve as a direct approach for formulation development. 
However, this method does not overcome the limitations of conventional SLN® and NLC® 
systems in terms of drug loading capacity.  
 
smartLipids®, the 3rd generation of lipid nanoparticle delivery system for lipophilic 
components were developed in 2014 (Müller et al., 2014). The particle matrix consists of 
typically more than five different lipids, including mono-, di- and triglycerides, fatty acids 
and fatty alcohols with various carbon chain lengths. In contrast to the classical lipid core 
structure, the complex “chaotic” lipid mixture gives them special properties such as the 
increased drug loading as well as the improved physical stability. More importantly, 
because of the mixing of multiple solid lipids and liquid lipid, smartLipids® are able to 
incorporate a variety of drugs, significantly reducing the workload of lipid screening by 
offering a more universal applicability. The complex lipid nanoparticle matrix has a low 





ordered crystallinity with an increased amount of imperfections, leading to improved drug 
loading capability. As demonstrated in Chapter 4, the loaded retinol in smartLipids® could 
be increased up to 20% (w/w), whereas SLN® and NLC® systems were limited to only 5%. 
Aside from increasing the drug loading capacity, the physical as well as chemical stability 
improved, showcasing two major advantages of this delivery method. This was evidenced 
by the fact that 87% of the enclosed retinol was detected in smartLipids® after 60 days 
(drug loading was 20%, w/w), whereas in a comparabled literature report using SLN® only 
62% was preserved after 1 week (drug loading was 5%, w/w) (Jenning and Gohla, 2001).  
 
For the development of smartLipids® formulations, a complex lipid matrix allowing high 
drug loading and high physical stability is required. Due to the complexity of the multi-lipid 
mixture, obtaining stable smartLipids® is more challenging compared to SLN® and NLC®.  
Such efforts are worth pursuing as evidenced by an optimized SLN® suspension showing 
at least 3 years of physical stability (Zur Mühlen et al., 1996). However, some formulations 
tend to aggregate or even form a gel after production or during the storage period (Freitas 
and Müller, 1999). Several studies show the aggregation and gelation phenomena 
depend strongly on for example the lipid matrix, composition and concentration of the 
surfactants, temperature, light and mechanical stress. For example, during crystallization, 
the increase of polymorphic transitions at the particle surface leads to the incomplete 
coverage from the surfactant, thus inducing instability in the nanoparticle system 
(Helgason et al., 2008; Siekmann and Westesen, 1994). However, the mechanism of 
aggregation and gelation procedure is still unclear and the unpredictability increases the 
difficulty of developing a stable lipid nanoparticle formulation. 
 
The primary aim of this study was not only the preparation of smartLipids® formulations 
with long-term physical stability, but also offering insights into key parameters surrounding 
the development of stable lipid nanoparticle systems. Therefore, the effects of various 
lipid combinations, surfactants and production parameters on the physical stability of 
smartLipids® were fully investigated. Lipids with different melting ranges and carbon chain 
lengths were used to form the lipid matrixes. Additionally, liquid lipid (Miglyol® 812) was 
added and the influence on the stability was also monitored. Four different surfactants at 





two different concentrations (1.5% and 3.0% w/w) were used for smartLipids® production. 
 




The solid lipids Imwitor® 372 P (V), Imwitor® 900 (F) P, Dynasan® 118, Softisan® 142 and 
Softisan® 154 were gifts from IOI Oleo GmbH (Hamburg, Germany). Compritol® 888 ATO 
and Precirol® ATO 5 were provided from Gattefossé (Bad Krozingen, Germany). 
Dynasan® 114, Dynasan® 116, Dynasan® P 60 (F) and Imwitor® 491 were donated from 
CREMER OLEO GmbH & Co. KG (Hamburg, Germany). Hydrogenated castor oil 
(Sternoil HCO*), 12-hydroxystearic acid (Sternoil 12-HSA*), behenyl alcohol (Vegarol 
2270*), palmitic acid (Palmac 98-16*), palm triple pressed acid (Palmac 55-16*), stearyl 
alcohol (Vegarol 1898*), cetyl stearyl alcohol (Vegarol 1618 50:50*), cetyl alcohol (Vegarol 
1698*), lauric acid (Palmac 99-12*), myristic acid (Palmac 99-14*) were gifts from Berg + 
Schmidt GmbH & Co. KG (Hamburg, Germany). Miglyol® 812 was bought from Caesar & 
Loretz GmbH (Hilden, Germany). Decyl glucoside and lauryl glucoside (both from Berg + 
Schmidt GmbH & Co. KG, Hamburg, Germany), Plantacare® 2000 UP (alkyl 
polyglycoside, BASF, Ludwigshafen, Germany) and Tween® 80 (Polyoxyethylene sorbitan 
monooleate, AMRESCO, Solon, USA) were used as surfactants. Ultra-purified water from 
Milli-Q apparatus (Millipore GmbH, Darmstadt, Germany) was used. All other reagents 
used in this study are analytical grade quality.  
* indicates the name from Berg + Schmidt GmbH & Co. KG. 
 
5.3.2. Production of smartLipids® 
 
All lipids used in smartLipids® formulations are listed in Table 5.1. The compositions of 
the lipid and water phase contained in the smartLipids® formulations are shown in 
Table 5.2 and 5.3. The nomenclature used for the of smartLipids® suspensions is 
illustrated in Fig. 5.1. In brief, smartLipids® nanosuspensions were produced using the 





hot high pressure homogenization procedure according to literature (Müller et al., 2000). 
The lipid phase was mixed and melted at 85 °C, and subsequently dispersed in the water 
phase at the same temperature. This was performed using an Ultra-Turrax (Janke & 
Kunkel GmbH, Germany) for one minute at 8,000 rpm. Following this, the obtained pre-
emulsion was homogenized using a Micron LAB 40 (APV Deutschland GmbH, Germany) 
for 3 cycles at 500 bar at 85 °C. 8 mL of the suspension is collected after each cycle for 
further analysis. Following homogenization, the produced hot nanosuspensions were 
cooled down to room temperature. 
 
For the production parameter investigation, the pre-emulsion of lipid composition 4 was 
homogenized for 5 cycles at 300, 400, 500, 600, 700, 800, 900 and 1000 bar, respectively. 
A 3 mL sample was collected after each cycle for further analysis. The produced hot 
























Table 5.1. An overview of all solid lipids used for the production of smartLipids® 
suspensions, classified by their chemical structures (glyceride, fatty acid or fatty alcohol) 
and sorted by ascending melting ranges. 
glyceride 
lipid trade name melting range [°C] type 
percentage 
[%] chain length 
Softisan® 142 42.0-44.0 
diglyceride 10 C12, C14, 
C16, C18 triglyceride 89 
Precirol® ATO 5 50.0-60.0 
monoglyceride 8-17 
C16, C18 diglyceride 54 
triglyceride 30 
Softisan® 154 53.0-58.0 triglyceride 100 C16, C18 
Imwitor® 900 (F) P 54.0-66.0 
monoglyceride 40-55 
C16, C18 diglyceride 30-45 
triglyceride 5-15 
Dynasan® 114 55.0-58.0 triglyceride 100 C14 
Imwitor® 372 P (V) 56.0-60.0 
monoglyceride 10-30 
C16, C18 diglyceride 
70-90 
triglyceride 
Dynasan® P60 58.0-62.0 triglyceride 100 C16, C18 




C22 diglyceride 52-54 
triglyceride 28-32 
Imwitor® 491 66.0-77.0 monoglyceride 100 C16, C18 
Dynasan® 118 69.0-73.0 triglyceride 100 C18 
hydrogenated 
castor oil 85.0-88.0 triglyceride 100 C18 
 
 





Table 5.1. continued 
fatty acid 
INCI melting range [°C] type 
percentage 
[%] chain length 
lauric acid 42.0-44.0 
 
C12 
myristic acid 52.0-54.0 C14 
palm triple pressed 
acid 55.0-56.5 C16, C18 
palmitic acid 61.0-63.0 C16 
12-hydroxystearic 
acid 72.0-80.0 C18 
fatty alcohol 
INCI melting range [°C] type 
percentage 
[%] chain length 
cetyl alcohol 47.0-50.0 
 
C16 
cetyl stearyl alcohol 48.0-52.0 C16, C18 
stearyl alcohol 56.0-59.0 C18 



















Table 5.2. The overview of the four lipid compositions (1, 2, 3 and 4) used for smartLipids® 
production, sorted by their melting range. 
solid lipids melting range [°C] 
lipid composition 
1 2 3 4 
lauric acid 42.0-44.0 - 10% - - 
Softisan® 142 42.0-44.0 - 10% - - 
cetyl alcohol 47.0-50.0 - 10% 10% - 
cetyl stearyl alcohol 48.0-52.0 - 10% 10% 10% 
Precirol® ATO 5 50.0-60.0 - 10% 10% 10% 
myristic acid 52.0-54.0 - 10% - - 
Softisan® 154 53.0-58.0 - 10% - - 
Imwitor® 900 (F) P 54.0-66.0 10% - - 10% 
palm triple pressed acid 55.0-56.5 10% - 10% 10% 
Dynasan® 114 55.0-58.0 - 10% - - 
stearyl alcohol 56.0-59.0 - 10% 10% 10% 
Imwitor® 372 P (V) 56.0-60.0 - 10% - 10% 
Dynasan® P60 58.0-62.0 - - - 10% 
palmitic acid 61.0-63.0 10% - 10% - 
Dynasan® 116 61.0-65.0 10% - - - 
behenyl alcohol 62.0-67.0 10% - 10% 10% 
Compritol® 888 ATO 65.0-77.0 10% - 10% 10% 
Imwitor® 491 66.0-77.0 10% - 10% 10% 
Dynasan® 118 69.0-73.0 10% - - - 
12-hydroxystearic acid 72.0-80.0 10% - - - 
hydrogenated castor oil 85.0-88.0 10% - 10% - 
 
 





Table 5.3. Compositions of smartLipids® suspensions produced using four different lipid 
compositions (1-4) and stabilized by various types of surfactants (decyl glucoside, lauryl 
glucoside, Tween® 80 and Plantacare® 2000 UP) and concentration (1.5 or 3.0%). 
formulation code lipid phase water phase lipid composition Miglyol® 812 surfactant water 
LM1-4/0 10% 0% 
1.5 / 3.0% 88.5 / 87.0% LM1-4/10 9% 1% 
LM1-4/20 8% 2% 
 
 
Fig. 5.1. Nomenclature explanation for the lipid phase of smartLipids® suspensions. 
For example: LM2/10 means that this smartLipids® suspension was produced using lipid 
composition 2 (c.f. Table 5.2) with additional 10% of Miglyol® 812.   
 
5.3.3. Characterization of the smartLipids®  
 
5.3.3.1. Photon correlation spectroscopy (PCS) 
 
The hydrodynamic diameter (z-ave) of the smartLipids® particles was measured by 
photon correlation spectroscopy (PCS, Zetasizer Nano ZS, Malvern Instruments, UK). 
The measuring range of the PCS is around 0.6 nm to 6 μm. PCS also gives the 
polydispersity index (PDI), providing information about the width of the particle size 
distribution. All samples were diluted with double distilled water (10 μL into 5 mL) at room 
temperature and each z-ave and PDI was calculated as the mean of 10 measurements. 
 
 





5.3.3.2. Laser diffractometry (LD) 
 
For potentially large particles or aggregates, laser diffractometry (LD) with a broad 
measuring range of 20 nm to 2,000 μm was performed using a Mastersizer 2000 (Malvern 
Instruments, UK), yielding the volume distribution of the particles. The particles were 
analyzed using the Mie theory applying 1.456 as the real refractive index (RI) and 0.01 
as the imaginary refractive index (IRI). The dispersion medium was distilled water and the 
stirring speed was 1,750 rpm. The D50 value represents 50% particles are equal to or 
lower than the given size. The same applies to the diameter D10, D90 and D95. Each 
value is the mean value of five measurements. 
 
5.3.3.3. Zeta potential (ZP) 
 
The zeta potential is a measurement of the electrostatic charge on the surface of the 
particles. Measurements were performed using a Zetasizer Nano ZS (Malvern 
Instruments, UK) in conductivity water (Milli-Q water adjusted to 50 µS/cm with NaCl 
solution at pH 5.5) and original dispersion medium (water phase of smartLipids® 
suspension). The electrophoretic mobility was converted into the zeta potential by the 
Helmholtz–Smoluchowski equation. The zeta potential measurement was conducted 
after production. All samples were diluted (10 μL into 5 mL) at room temperature and the 
mean values were calculated from three measurements. 
 
5.3.3.4. Differential scanning calorimetry (DSC) measurements 
 
Differential scanning calorimetry (DSC, Mettler Toledo, Germany) was used to investigate 
the melting behavior of lipid mixtures. 1-2 mg lipid composition 1-4 without Miglyol® 812, 
1.11-2.22 mg lipid composition 1-4 with 10% Miglyol® 812 (equal to 1-2 mg of solid lipid 
composition) and 1.25-2.50 mg lipid composition 1-4 with 20% Miglyol® 812 (equal to 1-
2 mg of solid lipid composition) were weighed into a standard aluminum pan (40 μL, 
Mettler Toledo, Switzerland) and sealed. The lipid mixtures were measured under 
nitrogen using an empty pan as reference. The samples were heated from 20 °C to 80 °C 





applying a heating rate of 10 K/min. The crystallinity index (CI) was calculated from the 
heat of fusion according to former literature to determine the degree of crystallinity of 
smartLipids® (Freitas and Müller, 1999). The CI was calculated relating to the mass of 
solid lipid in the mixture (not the total lipid mass composed of solid and liquid lipid). 
 
5.3.3.5. Long-term physical stability 
 
To determine the physical stability of smartLipids® in dependence of applied production 
parameters, each sample was stored at room temperature for 180 days. The physical 
stability was determined by particle size and size distribution changes, based on PCS 
and LD data, during the storage period (Vivek et al., 2007). 
 
5.4. Results and discussion 
 
5.4.1. Current benchmarks 
 
The lipid composition is one of the key parameters in controlling the characteristics of lipid 
nanoparticles (Borgia et al., 2005; Souto and Müller, 2006). Firstly, the number of the 
lipids influence the degree of distortion in the lipid matrix, and thus the loading capacity 
for the selected actives. For example, single solid lipid based SLN® limit the loading 
capacity while NLC® composed by solid-liquid-mixture improve active loading capacity. 
Secondly, the differences in crystallization behavior between the selected lipid 
composition and the active determine the structure of lipid nanoparticles during the 
cooling process (Müller et al., 2002b). Thus, an active-enriched shell or active-enriched 
core can be formed. Consequently, these different lipid matrix structures determine the 
release profile of the incorporated active. Thirdly, the recrystallization phenomena in the 
lipid matrix influence the stability of the lipid nanopartices because of the potentially 
formed unstable α-modification. During storage, this α-modification could transform into 
a more stable β-modification. The degree of polymorphic transformations is also 
influenced by the cooling procedure, playing a significant role in the overall stability of the 





system. In smartLipids®, the selected lipid composition is important as well, especially 
considering the lipid matrix contains more than five different lipids. Since crystallization 
behavior strongly depends on the cooling rate, the temperature profile of the lipid matrix 
in the cooling process is a key parameter in the development of lipid nanoparticles. The 
main consideration in selecting the lipid composition were the different melting ranges of 
the lipids. According to former studies, high melting range lipids, e.g. Compritol® 888 ATO 
(melting point 65.0-77.0 °C) (Jenning et al., 2000a), and low melting range lipids, e.g. 
Softisan® 142 (melting point 42.0-44.0 °C) (Radomska-Soukharev, 2007) were used to 
form lipid nanoparticles. Therefore, commonly used lipids (Table 5.1) from current 
publications within the melting range from around 42.0-85.0 °C were selected for 
smartLipids® preparation. Lipid composition 1 and 2 are combinations of high and low 
melting range lipids, respectively. Lipid composition 3 is composed by various melting 
range lipids with a broad range. Lipid composition 4 consists of medium melting point 
range lipids.  
 
5.4.2. The influence of melting points  
 
The physical stability was studied by monitoring the change in particle size of the 
smartLipids® during storage. An overview of the physical stabilities of smartLipids® 
suspensions is listed in Table 5.4. The suspensions produced with LM1/0 and LM3/0 all 
gelated after production regardless of surfactant or homogenization cycles, whereas the 
LM2/0 and LM4/0 groups yielded more stable formulations. Fig. 5.2 shows the most stable 
formulations, which were stable for 180 days of storage at room temperature. It is 
important to note that all of the 180-day-stable formulations were produced from lipid 
composition 2 and 4. Considering the melting range differences, the physical stabilities 
indicate that higher melting range lipids - making up lipid composition 1 and 3 - are more 
likely to form less stable lipid matrixes compared to lipid composition 2 and 4 formed by 
lower melting range lipids.  
 
One possible reason is the miscibility of the lipids. In general, a lower melting character 
represents superior solubility (Yamaoka et al., 1983). This indicates lipid compositions 





consisting of low melting point lipids tends to generate a highly homogenous lipid matrix. 
After the homogenization procedure, the lipid matrix of lipid nanoparticle inherits good 
solubility and miscibility and is likely to yield a stable lipid suspension system. In addition, 
the melting range distributions of the four lipid compositions are different. Table 5 shows 
the melting ranges of the four lipid composition and the corresponding numbers of the 
stable formulations. Lipid compositions 2 and 4 have narrow melting range distributions. 
Since lipids with smaller melting point differences tend to possess similar chemical 
structures, e.g. chain length and functional group, better miscibility can be expected 
(Greenhalgh et al., 1999). Therefore, lipid mixtures with a narrower melting range spreads, 
such as lipid composition 2 and 4, are more likely to form homogeneous and stable lipid 
matrix.  
 
Another possible explanation for the suspension instability relates to recrystallization 
phenomena, originating from polymorphic transformations of lipids. The polymorphic 
transformation from α-modification to the more stable β-modification poses a significant 
threat to the overall stability of the system (Helgason et al., 2008). During the cooling 
process, the solidification velocity of higher melting point lipids is faster than lower melting 
point lipids according to the Newton's law of cooling. Jenning’s research (Jenning et al., 
2000a) found that faster solidification resulted in the formation of α-modification, whereas 
the β-modification formed predominantly when cooling at a lower rate. For lipid 
composition 1 and 3 groups, a large amount of α-modification lipids formed a highly 
instable lipid matrix system, leading to the breakdown of the nanosuspension. 
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Table 5.4. An overview of the storage stabilities for all produced smartLipids® suspensions as a function of the lipid 
composition (1, 2, 3 and 4), oil content (0, 10 and 20%), surfactant type (DG: decyl glucoside; LG: lauryl glucoside; T: 
Tween® 80; P: Plantacare® 2000 UP), surfactant concentration (1.5 and 3.0%) and cycle number (1, 2 and 3). The number 
of days is specified for the stable formulation (e.g. 30, 60, 90, 120 and 180). No value is listed for formulations which 
aggregated or gelated one day after production (indicated by “-”). red: 30-60 days; yellow: 90-120 days; green: 180 days 
surfactant cycle 
number 
storage stability  [day] 
type concentration LM1/0,10 and 20 LM2/0 LM2/10 LM2/20 LM3/0 LM3/10 LM3/20 LM4/0 LM4/10 LM4/20 
DG 
1.5% 
1 - - - 30 - - - - - - 
2 - - - 60 - - - - - - 
3 - - 30 60 - - - - - - 
3.0% 1-3 - - - - - - - - - - 
LG 
1.5% 1-3 - - - - - - - - - - 
3.0% 1-3 - - - - - - - - - - 
T 
1.5% 
1 - - 180 120 - - - - - 180 
2 - - 90 120 - - - - - 90 
3 - - 30 30 - - - - - - 
3.0% 
1 - - 180 120 - 30 30 60 180 180 
2 - - 90 90 - 30 - 180 180 180 
3 - - - 90 - - - 60 - - 
P 
1.5% 
1 - - 60 90 - - - - - - 
2 - - 60 60 - - - - - - 
3 - 30 30 60 - - - - - - 
3.0% 
1 - - 90 - - - - - - - 
2 - - 120 - - - - - - - 
3 - - - - - - - - - - 
84 






LM2/10-1.5%T (1 cycle) 
  
LM2/10-3.0%T (1 cycle) 
  
LM4/0-3.0%T (2 cycles) 
Fig. 5.2. upper part 






LM4/10-3.0%T (1 cycle) 
  
LM4/10-3.0%T (2 cycles) 
  
LM4/20-1.5%T (1 cycle) 
Fig. 5.2. continued 






LM4/20-3.0%T (1 cycle) 
  
LM4/20-3.0%T (2 cycles) 
Fig. 5.2. The PCS data (z-ave and PDI) and LD data (D10, D50, D90 and D95) of the 
most stable smartLipids® suspensions up to 180 days. T is the abbreviation of Tween® 80. 
* the breaks in the y-axis are from 1 to 2 μm, and the scale changes above the break. 













Table 5.5. The number of lipids with low (40-60 °C), middle (60-80 °C) and high (> 80 °C) 
melting ranges in each lipid composition (1, 2, 3 or 4) correlated to their respective storage 
stabilities grouped in low (30-60 days), middle (90-120 days) and highest (180 days) 
stability. Stabilities are listed here independent of the cycle number. 
 melting range 
lipid composition 
1 2 3 4 
number of lipids in specific 
melting ranges 
40-60 °C 2 10 5 7 
60-80 °C 7 - 4 3 
> 80 °C 1 - 1 - 
 storage stability  
number of stable formulations 
30-60 days - 12 3 2 
90-120 days - 10 - 1 
180 days - 2 - 6 
 
5.4.3. The influence of surfactants 
 
5.4.3.1. The effect of the type of surfactant 
 
Surfactant type plays an important role regarding the particle size and distribution as well 
as physical stability of lipid nanoparticles (McClements, 2015). A variety of different 
stabilizers has been used for lipid nanoparticles, including ionic, non-ionic, amphoteric 
surfactants and polymeric stabilizers (Siekmann, 1994). Non-ionic surfactants, showing 
low skin sensitization potential and no toxicity, are widely used for stabilizing lipid 
nanoparticles (Kovacevic et al., 2011; Zhuang et al., 2010). In this study, four nonionic 
surfactants - decyl glucoside, lauryl glucoside, Plantacare® 2000 UP and Tween® 80 - 
were used to evaluate the influence on the physical stability.  
 
Plantacare® 2000 UP, which is produced by BASF and consists of decyl glucoside and 
lauryl glucoside, was used to investigate the influence of a surfactant mixture. 
smartLipids® prepared from lipid composition 2 stabilized by decyl glucoside, lauryl 
glucoside and Plantacare® 2000 UP showed very different stabilities (Table 5.6), even 
though they share similar molecular structures (Table 5.7). The number of stable 





formulations stabilized by Plantacare® 2000 UP were significantly more numerous than 
those stabilized by decyl glucoside, and were stable for longer periods of time as well. 
Moreover, all lipid nanoparticles stabilized by lauryl glucoside gelated after production, 
regardless of the surfactant concentrations or production parameters. The results show 
Plantacare® 2000 UP performed better stabilizing capability in smartLipids® systems than 
decyl glucoside and lauryl glucoside, indicating co-surfactants are likely to be more 
effective in stabilizing smartLipids® nanoparticles than formulations with single surfactant.  
 
Tween - a PEG-containing stabilizer - was used as a reference, because it proved in 
previous studies effective stabilizer for lipid nanoparticles. Table 5.6 shows that the total 
number of stable smartLipids® stabilized by Tween® 80 is much higher than those 
stabilized by decyl glucoside and Plantacare® 2000 UP. More importantly, only 
formulations stabilized by Tween® 80 showed stability up to 180 days. In addition, only 
lipid composition 2 could be successfully stabilized by decyl glucoside and Plantacare® 
2000 UP. However, formulations prepared from lipid composition 2, 3 and 4 stabilized by 
Tween® 80 show desirable stability properties. Therefore, Tween® 80 is the most effective 




















Table 5.6. Comparison of number of stable smartLipids® formulations being stabilized by 
the three surfactants decyl glucoside, Plantacare® 2000 UP and Tween® 80. Lauryl 
glucoside led to no stable formulations, thus is missing in following. The stabilities were 
evaluated cycle number independently and grouped in low (30-60 days), middle (90-120 
days) and highest (180 days) stability. 
lipid 
composition 
decyl glucoside Plantacare® 2000 UP Tween® 80 
number of stable 
formulations 
number of stable 
formulations 




















LM1/0-20 - - - - - - - - - 
LM2/0 - - - 1 - - - - - 
LM2/10 1 - - 3 2 - 1 2 2 
LM2/20 3 - - 2 1 - 1 5 - 
LM3/0 - - - - - - - - - 
LM3/10 - - - - - - 2 - - 
LM3/20       1 - - 
LM4/0 - - - - - - 2 - 1 
LM4/10 - - - - - - - - 2 

















Table 5.7. Overview of surfactants used for the production of smartLipids® suspensions, 
showing surfactants chemical structure, molecular weight (MW) and HLB values after 
Davies. 





















C18 1310 15 
 
5.4.3.2. The effect of HLB value 
 
HLB theory proposes the HLB value of the surfactant should match the HLB values of the 
lipids in order to produce physically stable smartLipids® systems. Additionally, the 
required HLB value decreases with an increasing amount of liquid lipid in the matrix 
(Kovacevic et al., 2011; Myers, 2005). This was confirmed by lipid composition 2 stabilized 
by 3% (w/w) Tween® 80. LM2/10-3.0%T with 1 cycle shared the same lipid composition 
and production parameters with LM2/20-3.0%T with 1 cycle, the only difference being the 
content of liquid lipid (Miglyol® 812, 10% versus 20%). Table 5.4 indicates LM2/10-3.0%T 
with 1 cycle and LM2/20-3.0%T with 1 cycle were stable for 180 and 120 days, 





respectively. According to the HLB theory, the required HLB value of LM2/20 should be 
lower than LM2/10. Thus, the stability of LM2/20-3.0%T with 1 cycle decreased.  
 
Table 5.6 shows the most stable smartLipids® suspensions were stable for 180 days. 
Interestingly, all the 180-day-stable nanosuspensions were stabilized by Tween® 80. 
Since Tween® 80 possesses the longest carbon chain (C18, Table 5.7) and highest HLB 
value (15), the HLB values of the four lipid mixtures are likely around or higher than 15. 
Therefore, the surfactant with high HLB value is more capable of stabilizing the lipid 
mixture. This is underlined further by the stabilities formulations derived from LM2/10. The 
most stable (180 days) lipid suspensions of LM2/10 were stabilized by Tween® 80 with 
the HLB value of 15. With lower HLB value surfactants decyl glucoside (12) and 
Plantacare® 2000 UP (12), the stability decreased to 60 and 120 days, respectively. With 
lauryl glucoside, having the lowest HLB value of 11, no stable formulation could be 
produced. 
 
5.4.3.3. The effect of surfactant concentration 
 
High concentrations of surfactants decrease the surface tension at the water/lipid 
interface and facilitates particle partition (McClements, 2015). Moreover, insufficient 
surfactant induces instability as recrystallization processes become more favorable 
(Weiss et al., 2008). During the cooling process, the α-modification may transfer into the 
needle-like-structured β-modification with increased surface areas. If the newly formed 
surface area is not sufficiently covered by surfactant molecules, hydrophobic interactions 
may lead to flocculation, and thus instability. Formulation LM4/0-1.5%T gelated 
immediately, whereas increasing the surfactant concentration to 3.0% made the 
formulation highly stable (180 days). Regarding this stability difference, Helgason 
(Helgason et al., 2009) offered an explanation. When surfactant concentrations are high, 
surfactant tail groups are packed tightly at the lipid-water interface. These tightly packed 
tails result in a solid-like characteristic. Therefore, at high surfactant concentrations, the 
lipid particles are surrounded by a rigid “shell” formed by sufficient surfactant tail groups. 
This “shell” acts as a steric constraint and slows down or restricts the particle movement, 





resulting in the increased physical stability. 
 
However, higher surfactant concentrations do not always lead to higher stability. 
smartLipids® nanosuspensions prepared with LM2/10 and LM2/20 as lipid matrix 
stabilized by 1.5% w/w decyl glucoside were stable up to 60 days. Upon increasing the 
surfactant concentration to 3.0%, the formulation gelated after production. The results 
show that in this case, an increased amount of surfactant decreased the stabilities of lipid 
nanoparticles. According to the production procedure, the lipid mixture formed a 
nanoemulsion at elevated temperature first, followed by the formation of smartLipids® 
upon cooling down. The nanoemulsion state significantly affects the state of final 
smartLipids® nanosuspension. The physical stability of nanoemulsions is influenced by 
Ostwald ripening (Adams et al., 2007). In Ostwald ripening theory, nanoemulsion tends 
to generate a single drop and the larger size difference in this nano system exists, the 
higher rate of Ostwald ripening happens. The Lifshitz–Slesov–Wagner (LSW) theory 











in which r is the average radius of droplets; t is the storage time; C∞ is the bulk phase 
solubility; γ is the interfacial tension; Vm is the molar volume; D is the diffusion in the 
continuous phase; ρ is the density of the oil; R is the gas constant; T is the absolute 
temperature. 
 
The increasing amount of surfactant decreases the droplet size, which in turn increases 
the Brownian diffusion, leading to the enhancement of Ostwald ripening rate. With higher 
surfactant concentrations, lower HLB value (here is decyl glucoside) surfactant molecules 
may preferentially accumulate at the interface, resulting in reduction of the Gibbs elasticity, 
inducing the increase of Ostwald ripening rate (Tadros et al., 2004) as well. In the 
smartLipids® preparation process, this instability of the nanoemulsion results in gelation 
during cooling.  
 
 





5.4.4. The melting behavior of lipid compositions 
 
Due to the multiple lipids present in the smartLipids® lipid matrix, the solubility and 
miscibility of lipids determine the homogeneity of the lipid matrix, and thus influence the 
stability of the entire lipid suspension system. Experimentally, DSC was employed to 
investigate the melting behavior of the four lipid compositions and miscibility was 
predicted.  
 
Fig. 5.3 shows the melting behavior of four lipid compositions. The DSC graph of lipid 
composition 2 with 0% Miglyol® 812 (Fig. 5.3 upper right) shows there is a broad peak 
around 30 °C apart from the main peak (around 43 °C). This indicates the lipid mixture 
without oil was not molecularly dispersed. The immiscibility of the lipid matrix formed by 
lipid composition 2 might not yield stable smartLipids® nanosuspensions, thus liquid lipid 
Miglyol® 812 was added into the solid lipid compositions. After adding 10% and 20% 
Miglyol® 812 (compared to lipid matrix), the 30 °C peak of lipid composition 2 disappeared, 
indicating more homogeneous lipid matrixes were obtained by addition of liquid lipid.  
 
The detailed DSC results of all lipid compositions are shown in Table 5.8. After adding 
Miglyol® 812 into the four lipid compositions, all the main melting points shifted to lower 
temperatures in a concentration dependent manner. For example, the melting points of 
LM3/0, LM3/10 and LM3/20 were 55.49 °C, 54.07 °C and 53.70 °C, respectively. This 
depression also occurred in enthalpy values as well as crystallinity indices (CI). This 
phenomenon aligns with other studies (Jenning et al., 2000a; Kovacevic et al., 2011), 
indicating the addition of a liquid lipid distorts the structure of the matrix. 
 
Triglycerides are known to exist in multiple modifications (Hernqvist, 1988; Saupe et al., 
2005), for example in α-modification (thermodynamic instable modification) and β-
modification (thermodynamic stable modification). As it was mentioned in section 5.4.1., 
the polymorphic transition is one of the main sources of instability in the lipid matrix. The 
DSC results show no new peak emerging after adding Miglyol® 812 into the four lipid 
compositions. Therefore, the addition Miglyol® 812 did not induce polymorphic transitions, 
making it a suitable stabilization tool in smartLipids® production. In addition, the 





thermograms of lipid combination 4 show a peak shoulder at higher temperatures (around 
63 °C), which becomes more pronounced with higher amounts of Miglyol® 812. This also 
occurred in another study (Jenning et al., 2000a), and a possible reason is the solubility 
of Miglyol® 812 in different modifications of lipids is not identical. This inconsistency 
induced different extend of melting point shift, leading to an obvious separation of the two 
peaks. 
 
Nevertheless, the DSC measurements show all the lipid mixtures’ melting points were 
higher than 42 °C, except for lipid composition 2 with 0% Miglyol® 812. This is especially 
important for dermal application, as the skin temperature of humans is 32 °C (Saupe et 




lipid composition 1 lipid composition 2 
  
lipid composition 3 lipid composition 4 
Fig. 5.3. Differential scanning calorimetry thermograms (20-80°C) of all four lipid 
compositions (1, 2, 3 and 4) with increasing amount of Miglyol® 812 from 0, 10 to 20% 
measured at a heating rate of 10 K/min. 





Table 5.8. Melting peaks, enthalpy and crystallinity index (CI) for each lipid composition 
as measured by DSC. 
lipid composition peak 1 [°C] peak 2 [°C] peak 3 [°C] enthalpy [J/g] CI [%] 
LM1/0 47.17 55.80 - -107.47 100 
LM1/10 45.83 55.70 - -97.10 90.3 
LM1/20 42.24 53.38 - -68.00 63.3 
LM2/0 30.76 43.59 56.29 -66.78 100 
LM2/10 - 43.58 55.45 -52.85 79.1 
LM2/20 - 42.19 55.29 -45.76 68.5 
LM3/0 55.49 - - -84.82 100 
LM3/10 54.07 - - -72.22 85.1 
LM3/20 53.70 - - -58.75 69.3 
LM4/0 57.02 63.50 - -76.43 100 
LM4/10 56.00 63.16 - -59.87 78.3 
LM4/20 54.23 63.11 - -55.73 72.9 
 
5.4.5. The influence of the addition of Miglyol® 812 on physical stability 
 
Lipid composition 1-4 with and without the addition of Miglyol® 812 were all used for 
smartLipids® preparation, and the physical stabilities of the suspensions were 
investigated. An overview of the physical stabilities is listed in Table 5.4. It is obvious that 
following the addition of Miglyol® 812, the physical stability of all mixtures improved. For 
example, Formulation LM2/0 stabilized by 1.5% w/w decyl glucoside gelated regardless 
of the number of homogenization cycles, but after adding 10% and 20% Miglyol® 812 
remained stable for 30 and 60 days respectively. This improved physical stability also 
occurred for lipid composition 3 (stabilized by 1.5% w/w Tween® 80) and 4 (stabilized by 
1.5% w/w Tween® 80). The proposed cause for this is that the addition of liquid lipid 
causes a decrease in size of the lipid nanoparticles, since a lower viscosity lipid phase 
can be dispersed more easily (Jenning et al., 2000b). For example, the mean particle size 
(z-ave) of LM4/0-3.0%T after 1 homogenization cycle was 269 nm, and that of LM4/10-
3.0%T after 1 cycle was 180 nm (Fig. 5.4). These two suspensions were stable for 60 and 
180 days, respectively, indicating the addition of liquid lipid reduces the particle size and 
increases the physical stability. 
 





However, indefinitely increasing the amount of liquid lipid does not always yield more 
stable formulations. LM2/20-1.5%T undergoing 1 homogenization cycle were less stable 
(120 days) compared to LM2/10-1.5%T after 1 cycle (180 days), even though LM2/20-
1.5%T with 1 cycle contained more Miglyol® 812 (Fig. 5.4). Additionally, LM1/0, LM1/10, 
and LM/1/20 yielded no stable formulation. Following the surfactant influence discussed 
in section 5.4.3., the addition of liquid lipid may change the optimal HLB value of 
surfactant, making the previously optimal surfactant type and concentration less suitable. 
Therefore, adding liquid lipid enhances the general physical stability but constant addition 




LM2/10-1.5%T (1 cycle) 
  
LM2/20-1.5%T (1 cycle) 
Fig. 5.4. upper part 






LM4/0-3.0%T (1 cycle) 
  
LM4/10-3.0%T (1 cycle) 
Fig. 5.4. The PCS data (z-ave and PDI) and LD data (D10, D50, D90 and D95) of LM4/0-
3.0%T (1 cycle), LM4/10-3.0%T (1 cycle), LM2/20-1.5%T (1 cycle) and LM2/10-1.5%T (1 
cycle).  
* the breaks in the y-axis are from 1 to 2 μm, and additionally mark a change in the scale. 
 
5.4.6. The influence of production parameters 
 
Aside from the lipid combination and surfactant, another important factor in producing 
stable smartLipids® is optimized production parameters. smartLipids® suspensions were 
produced using high pressure homogenization. In order to keep all lipid mixtures in a 
molten state during the homogenization process, lipid nanoparticles were produced at 





85 °C. In general, homogenization favors the generation of small particles with a narrow 
particle size distribution, and enhances the physical stability of the suspension system. 
However, intermittent sampling after each homogenization cycle shows a decreasing 
physical stability with an increasing number of homogenization cycles for some 
formulations (Table 5.4). LM2/10-3.0%T after 1 homogenization cycle was stable for 180 
days, but the stable lifetime decreased to 90 days after 2 cycles, and after 3 cycles the 
formulation gelated instantly following production. The z-ave and size distribution data 
during storage time are shown in Fig. 5.5. The z-ave values of LM2/10-3.0%T produced 
with 1 and 2 cycles were 188 and 166 nm, respectively. LM2/10-3.0%T after 1 cycle 
showed the best stability. After 180 days, 90% of the lipid nanoparticles were still smaller 
than 0.3 μm indicating good physical stability, even though the D95 value was around 5 
μm by this time. As a contrast, LM2/10-3.0%T following 2 cycles aggregated after 
120 days. 
 
During homogenization, the high thermal energy and shear forces contribute to several 
effects: (1) reducing the size of the particles, (2) heating the lipid suspension and (3) 
increasing the kinetic energy of the particles. In the production process, the 
homogenization procedure first contributes to reducing the size of the lipid particles. 
Following a certain number of cycles, the lipid nanoparticles cannot be further reduced in 
size. The high energy is then mainly dispersed as heat and particle kinetic energy, both 
of which contribute to faster particle movement. This high kinetic energy causes more 
frequent and intense collisions between nanoparticles, and then potentially damages the 
surfactant film at the lipid nanoparticles’ surface, causing aggregation (Freitas and Müller, 
1999). 
 
In order to develop an in-depth understanding on how the homogenization procedure 
affects the physical stability of lipid nanoparticles, LM4/0-3.0%T was selected for this 
study. This is because Table 5.4 shows that the number of homogenization cycles has a 
significant influence on the stability of this formulation. Thus, LM4/0-3.0%T was produced 
using various pressures (300, 400, 500, 600, 700, 800, 900 and 1000 bar), and with 1 to 
5 homogenization cycles. The stability was monitored up to 90 days (Table 5.9). When 





the pressure was increased from 300 up to 900 bar, no noticeable decrease in stability 
could be observed. However, the suspension produced at 1000 bar shows obvious 
instability, and the best formulation was stable for only 30 days. In addition, all 
formulations gelated immediately following a 5th homogenization cycle. This is in line with 
the expected frequent high-energy collisions between particles as discussed above. In 
addition, the data differs from the former results in Table 5.4 where the formulations show 
instabilities after 3 homogenization cycles. A possible cause for this discrepancy is that 
the total sample volume for each following homogenization cycle was different.  In 
previous studies, 8 mL samples were collected for further analysis out of the 40 mL batch, 
but for LM4/0-3.0%T study only 3 mL of the suspension was collected following each 
cycle, leading to the different average energy among particles. 
 
According to the stability investigations, for smartLipids® preparation 300-900 bar with 
two homogenization cycles are preferable and further increase of homogenization 




LM2/10-3.0%T (1 cycle) 
Fig. 5.5. upper part 






LM2/10-3.0%T (2 cycles) 
Fig. 5.5. The PCS data (z-ave and PDI) and LD data (D10, D50, D90 and D95) of LM2/10-
3.0%T with 1 and 2 cycles. 
* the breaks in the y-axis are from 1 to 2 μm, and additionally mark a change in the scale. 
 
Table 5.9. The overview* of the storage stabilities of LM4/0-3.0%T smartLipids® 
suspensions applying various homogenization cycles. No day value is given for 
formulations aggregated or gelated shortly after production. 
 storage stability  [day] 
pressure [bar] 1 cycle 2 cycles 3 cycles 4 cycles 5 cycles 
300 90 90 90 90 - 
400 90 90 90 90 - 
500 < 30 90 90 90 - 
600 90 90 90 < 30 - 
700 < 30 90 90 90 - 
800 < 30 90 90 90 - 
900 90 90 < 30 90 - 
1000 < 30 30 < 30 < 30 - 
* detailed results of the stability are shown in the Appendix Fig. A2. 
 
5.4.7. The influence of the zeta potential 
 
The zeta potential is a commonly used value aiding physical stability prediction in the 
case of electrostatic stabilization. The higher the zeta potential is, the higher is the 
electrostatic repulsion force among the particles, and therefore the physical stability of 





the system. The zeta potential measured in conductivity water (50 µS/cm, adjusted by 
NaCl) represents the surface charge of the nanoparticles (Helmholtz potential). The zeta 
potential measured in original medium is a measure for the thickness of the diffuse layer. 
If the diffusive layer is thinner, the potential decays more strongly leading to a lower 
measured zeta potential. According to literature (Müller et al., 1996), zeta potential values 
higher than |30 mV| in the original medium indicate stable suspensions. Table 5.10 shows 
the overview of zeta potential values of smartLipids® suspensions. The zeta potential of 
LM2/10-1.5%T after 1 homogenization cycle in original medium was -37.9 mV, and the 
formulation was stable for 180 days, which is in accordance with the predicted stability 
based on electrostatic repulsion between the particles. Therefore, high zeta potential 
values appear to be a useful tool for the prediction of the long-term stability of 
smartLipids®. 
 
However, the zeta potential value of the stable (180 days) smartLipids® suspension 
LM4/20-3.0%T with 2 cycles in original medium was only -12.0 mV. Despite this low 
absolute zeta potential value, the mean particle size remained perfectly unchanged 
(around 130 nm) for 180 days. The LD result confirms this observed stability, as the size 
distribution remains unchanged with a D95 value of around 0.3 μm throughout the storage 
timeframe. In this case, the stability does not solely originate from electrostatic repulsion, 
but additional steric stabilization may play a role as well (Mitri et al., 2011). Previously, 
Tween® 80 was already used as steric stabilizer for solid lipid nanoparticles in C. Olbrich’s 
research, which exhibited a similarly low zeta potential value (Olbrich and Müller, 1999).  





Table 5.10. Zeta potential (ZP) of smartLipids® formulations measured in conductivity 
water (CW) and original medium (OM), correlated to respective storage stabilities.  





ZP [mV] storage stability 
[day] type concentration CW OM 
LM2/0 P 1.5% 3 -56.5 -19.0 30 
LM2/10 
DG 1.5% 3 -68.0 -37.8 30 
T 1.5% 
1 -60.3 -37.9 180 
2 -50.7 -29.5 90 
3 -52.9 -24.1 30 
T 3.0% 1 -52.6 -26.8 180 2 -41.8 -19.6 90 
P 1.5% 
1 -66.5 -26.8 60 
2 -69.8 -27.0 60 
3 -65.0 -20.0 30 
P 3.0% 1 -62.1 -14.7 90 2 -60.4 -14.2 120 
LM2/20 
DG 1.5% 
1 -68.8 -34.8 30 
2 -68.7 -39.1 60 
3 -62.9 -34.2 60 
T 1.5% 
1 -59.7 -39.6 120 
2 -51.8 -30.5 120 
3 -46.5 -24.5 30 
T 3.0% 
1 -55.5 -28.6 120 
2 -54.6 -20.5 90 
3 -38.4 -15.3 90 
P 1.5% 
1 -74.8 -34.0 90 
2 -72.5 -29.1 60 
3 -75.3 -27.2 60 
LM3/10 T 1.5% 1 -41.4 -6.97 30 2 -33.8 -5.18 30 
LM3/20 T 1.5% 1 -43.4 -9.17 30 
LM4/0 T 3.0% 
1 -43.9 -19.5 180 
2 -42.1 -18.2 180 
3 -40.6 -17.1 60 
LM4/10 T 3.0% 1 -46.4 -16.2 180 2 -41.2 -14.1 180 
LM4/20 
T 1.5% 1 -49.2 -28.3 180 2 -41.5 -24.1 90 
T 3.0% 1 -41.2 -15.7 180 2 -34.2 -12.0 180 






smartLipids® suspensions with excellent physical stability were successfully developed in 
this study. Furthermore, the key factors in the development of stable lipid nanoparticle 
systems were thoroughly investigated. In summary, physically stable smartLipids® 
nanosuspensions can be obtained by using the low melting points lipids, surfactants with 
relative high HLB values as well as adding liquid lipid and applying only 1 or 2 
homogenization cycles.  
 
Identifying key parameters in both lipid selection and production parameters led to the 
successful development of stable smartLipids® suspensions. Future research efforts can 
be dedicated to further parameters (e.g. different storage temperature and packing 
material, etc.) as well as the incorporation of actives into smartLipids®. In the latter regard, 
this study has already shown preliminary success by demonstrating that adding liquid 
lipid improves the physical stability. Compared to the mixture of various solid lipids, the 
addition of liquid lipid further increases the amount of imperfections in the lipid matrix, 
which is indicative of possibly enhanced drug loading capacity. This improvement 
underlines the great potential of smartLipids® for practical application. 
 
Nowadays, smartLipids® products are already on the market (e.g. BergaCare 
smartLipids® (Olechowski et al., 2016)), showing that further development causes the 
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α-tocopherol, an antioxidant possessing the highest biological activity in vitamin E 
subfamilies, finds widespread application in protecting the human skin against 
environmental damage. Incorporating α-tocopherol into lipid nanoparticles enhances its 
chemical stability as well as skin penetration rate, making this method highly suitable for 
dermal application. In this study, solid lipid nanoparticles (SLN®) produced using two 
different lipids, carnauba wax and cetyl palmitate, were selected for α-tocopherol loading. 
The lipid nanoparticles were loaded with 5% and 10% α-tocopherol (w/w, compared to 
the suspension). The mean particle sizes of all formulations were in the nano-range one 
day after production, and zeta potential values measured in the original medium were 
higher than |40 mV|. Among all the produced lipid suspensions, SLN® loaded with 10% 
α-tocopherol, produced with carnauba wax and undergoing three homogenization cycles 
showed the highest drug loading capability as well as best short-time stability. The thermal 




As life expectancy increases around the globe, skin aging has been receiving an ever-
growing amount of attention. Skin aging can be attributed to several factors, including 
environmental exposure to ultraviolet (UV) radiation, hormonal changes and metabolic 
processes (Rittié and Fisher, 2002). Unlike most other organs, the human skin is directly 
exposed to the environment, continuously coming into contact with free radicals. 
Therefore, environmental damage is of considerable significance for skin aging (Fisher et 
al., 2002). One of the primary environmental causes of skin aging is UV (UVA and UVB) 
irradiation from sunlight, and the effects of UVA (320-400 nm) and UVB (290-320 nm) in 
skin are different (Gange et al., 1985). UVA elicits premature ageing, whereas UVB 
causes erythema and skin cancer induced by DNA damage (McVean and Liebler, 1997; 
Wissing and Müller, 2001).  
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There is strong evidence indicating that Vitamin E can be used as an antioxidant for 
pharmaceutical and cosmetic products (Schmidt, 1993), and the antioxidants were shown 
to reduce skin aging by exposure to UV radiation (Trombino et al., 2009). Vitamin E, 
consists of two subfamilies: tocotrienols and tocopherols, and each of them was 
designated as four forms: α, β, γ and δ. Although the structures of the eight molecules 
are similar, their biological activities are different owing to the presence of three double 
bonds in the isoprenoid side chain (Musalmah et al., 2005; Serbinova et al., 1991). Among 
the eight forms, α-tocopherol has the highest biological activity as a chain-breaking 
antioxidant for preventing cell damage from free radicals (Brigelius-Flohe and Traber, 
1999; Zigoneanu et al., 2008). Some cellular macromolecules, such as proteins and DNA, 
can be attacked by highly reactive free radicals, resulting in impairment of the cell function. 
Upon contact with a peroxyl radical generated by UV light, α-tocopherol acts as a radical 
trap and becomes an α-tocopheroxyl radical by losing its phenolic hydrogen atom. This 
more stable radical can subsequently react with a second radical, or be reduced by for 
example ascorbic acid (vitamin C), thereby regenerating the α-tocopherol (Brantley et al., 
2000). Due to the effective impact on quenching oxidative chain reactions, α-tocopheroxyl 
radical protects the normal cells against oxidative damage.  Aside from understanding the 
mechanism on a molecular scale, the ability of α-tocopherol to minimize the skin damage 
caused by UV radiation is also proven (Wissing and Müller, 2001). Furthermore, as a skin 
care active, α-tocopherol increases cell proliferation and moisture content of the skin. This 
effect further aids in protecting the skin against photoaging (Fuchs, 1998). Based on the 
pronounced skin-protecting effects of a-tocopherol, the development of the α-tocopherol-
loaded delivery system for dermal application is very desirable. 
 
There are currently several methods for the delivery of α-tocopherol, including 
nanoemulsions (Sharif et al., 2017; Teixeira et al., 2017), liposomes (Sahari et al., 2017) 
and polymeric nanoparticles (Alqahtani et al., 2015). With the purpose of improving 
physical and chemical stabilities of the incorporated active, solid lipid nanoparticles (SLN®) 
were developed in 1991 as an alternative drug delivery system to nanoemulsions, 
liposomes and polymeric nanoparticles (Lucks and Müller, 1991; Pardeike et al., 2009). 
SLN® consist of a solid lipid instead of a liquid lipid, which is commonly used in emulsion, 
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and possess the following advantages over other conventional systems used for topical 
administration: (1) improved chemical stability of the incorporated active, e.g. retinol 
(Jenning and Gohla, 2001); (2) high compatibility with human skin and enhanced 
penetration of the incorporated active (Souto and Müller, 2008); (3) increased drug 
loading capability (Ding et al., 2018); (4) easy to scale up preparation, and low toxicity 
because of the avoidance of organic solvents (Pardeike et al., 2009); (5) an increase of 
the water content of human skin because of an occlusive effect of SLN® (Wissing et al., 
2001); (6) a high UV-blocking potential (Wissing and Müller, 2001).  
 
Several studies on the α-tocopherol-loaded SLN® delivery systems have been published 
(de Carvalho et al., 2013; Dingler et al., 1999; Trombino et al., 2009), and have made 
positive contributions to pharmaceutical and cosmetic applications of α-tocopherol. 
However, only limited researches focus on improving the drug loading capability of α-
tocopherol. Therefore, the aim of the current study was to produce α-tocopherol-loaded 
SLN® formulations for topical application with increased drug loading. Both carnauba wax 
and cetyl palmitate were used for forming lipid matrixes of SLN®. In addition, the 
characteristics of the produced SLN® suspensions were comprehensively investigated, 
including particle size and particle size distribution, zeta potential and thermal behavior. 
 




Cetyl palmitate was a gift from Dr. Rimpler GmbH (Wedemark, Germany). Tego Care 450 
(polyglycerol methylglucose distearate) was provided by Evonik Nutrition & Care GmbH 
(Essen, Germany). DL-α-tocopherol was purchased from Alfa Aesar (Kandel, Germany).  
Carnauba wax was obtained from Kahl (Trittau, Germany). Ultra-purified water from Milli-
Q apparatus (Millipore GmbH, Darmstadt, Germany) was used. All other reagents used 
in this study are analytical grade quality. 
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6.3.2. Production of lipid nanoparticle suspensions 
 
The solid lipid nanoparticle suspensions were produced using cetyl palmitate or carnauba 
wax, with 1.8% Tego Care 450 as stabilizer and loaded with two different amounts of 
tocopherol (5% and 10%, w/w). The compositions of the lipid and water phase contained 
in the SLN® formulations are shown in Table 6.1. Solid lipid nanoparticles were produced 
using a hot-homogenization technique with a high-pressure homogenizer Micron Lab 40 
(APV Homogeniser GmbH, Germany). Briefly, the lipids were melted at 95 °C (carnauba 
wax) or 85 °C (cetyl palmitate) and then α-tocopherol was added. The aqueous phase 
was added into the lipid phase and dispersed using an Ultra-Turrax (Janke & Kunkel 
GmbH, Germany) at 8000 rpm for 1 min. This mixture was homogenized at 95 °C 
(carnauba wax) or 85 °C (cetyl palmitate) and 500 bar, undergoing a total of three 
homogenization cycles. 6 mL of the suspension was collected after each cycle for further 
analysis. Following production, the produced hot lipid nanoparticle suspensions were 
cooled down to room temperature. 
 
Table 6.1. An overview of the compositions of α-tocopherol-loaded SLN® suspensions, 
produced using carnauba wax or cetyl palmitate and stabilized by Tego Care 450. CW: 
carnauba wax; C: cetyl palmitate. 
name 
lipid phase (w/w) water phase (w/w) 








450 Milli Q 
5% tocopherol-CW-SLN 15.0% - 5.0% 
1.8% 78.2% 10% tocopherol-CW-SLN 10.0% - 10.0% 5% tocopherol-C-SLN - 15.0% 5.0% 
10% tocopherol-C-SLN - 10.0% 10.0% 
 
6.3.3. Characterization of the lipid nanoparticles  
 
6.3.3.1. Photon correlation spectroscopy (PCS) 
 
The mean particle size (z-ave) of the lipid nanoparticles was measured by photon 
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correlation spectroscopy (PCS, Zetasizer Nano ZS, Malvern Instruments, UK). PCS also 
yields the polydispersity index (PDI), which describes the width of the particle size 
distribution. All samples were diluted with double distilled water (10 μL into 5 mL) at room 
temperature and each z-ave and PDI was calculated from 10 measurements. 
 
6.3.3.2. Laser diffractometry (LD) 
 
In order to detect larger particles or aggregates, laser diffractometry (LD, Mastersizer 
2000, Malvern Instruments, UK) with a measuring range of 20 nm to 2,000 μm was 
employed. The following measurement parameters were used: 1.456 for real refractive 
index and 0.01 for imaginary refractive index. The dispersion medium was distilled water 
and the stirring speed was 1,750 rpm. Results are expressed as volume weighted 
diameters 10%, 50%, 90% and 95% (D10, D50, D90 and D95). The D95 value represents 
95% of the particle diameters are equal to or lower than the given size. The same illusion 
was applied to the D10, D50 and D90. Each value is given as the average of five 
measurements. 
 
6.3.3.3. Zeta potential (ZP) 
 
Zeta potential is a measure of the electrostatic charge on the nanoparticles’ surface. The 
zeta potential measurement was performed using a Zetasizer Nano ZS (Malvern 
Instruments, UK) in conductivity water (50 µS/cm, pH 5.5) or original medium (water 
phase of SLN suspension). The electrophoretic mobility was converted into the zeta 
potential by the Helmholtz–Smoluchowski equation. All samples were diluted (10 μL into 
5 mL) at room temperature and the mean values were calculated from three 
measurements.  
 
6.3.3.4. Differential scanning calorimetry (DSC) measurements 
 
Differential scanning calorimetry (DSC, Mettler Toledo, Germany) was used to investigate 
the thermal behavior of the SLN® suspensions. The lipid nanoparticle suspension 
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(approximately 1-2 mg of lipid) was weighed into a standard aluminum pan (40 μL, Mettler 
Toledo, Switzerland) and sealed.  The samples were measured under nitrogen, using an 
empty pan as reference. The samples were heated from 20 °C to 95 °C at a heating rate 




ΔHbulk material × concentrationlipid phase 
× 100 
where ΔHSLN and ΔHbulk material are the melting enthalpies (J/g) of the lipid nanoparticles 
and bulk material, respectively. The concentration of the lipid phase for lipid nanoparticles 
was 20% w/w. 
 
6.3.3.5. Physical stability 
 
To determine the physical short-term stability of SLN® suspensions, each sample was 
stored at room temperature for 7 days. The physical stability was by measuring the 
particle size in regular intervals during the storage period (Vivek et al., 2007). Particle size 
analysis, including mean particle size and size distribution, was conducted using PCS 
and LD on the day following production (= day 1) and on the 7th day after production (= 
day 7). 
 
6.4. Results and discussion 
 
6.4.1. Particle size characterization determined by PCS 
 
Fig. 6.1A shows the particle diameters (z-ave) and polydispersity indices (PDI) of the 
produced SLN® suspensions as measured by PCS, one day after production. The particle 
size clearly decreases with an increasing number of homogenization cycles for each 
formulation. Furthermore, homogenization narrows the size distribution. This effect is 
already established in literature, and is caused by the shear forces during the 
homogenization process, which break the lipid particles to nano size (Müller et al., 2000). 
After three homogenization cycles, all lipid nanoparticle suspensions measured had a 
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mean particle size lower than 350 nm and a PDI less than 0.25. The impact of 
homogenization cycle on reducing the particle size was more pronounced for SLN® 
suspensions produced with carnauba wax. In addition, the star which marks the 5% 
tocopherol-C-SLN formulation with 3 cycles shows the particle size (280 nm) of the same 
formulation from literature (Dingler et al., 1999). The small difference proves the 
reproducibility of the formulation which is significant for further industrialization.    
 
Fig. 6.1B shows the mean particle size and PDI on the 7th day after production. Compared 
to Fig. 6.1A the particle size or size distribution did not change significantly. The lipid 
nanoparticle suspensions produced with different numbers of homogenization cycles all 
remained in nano-range with narrow size distributions. Thus, all lipid nanoparticle 





Solid lipid nanoparticles (SLN®) for the delivery of α-tocopherol – an efficient method for 







Fig. 6.1. Particle diameters (z-ave, bars) and polydispersity indices (PDI, dots) of α-
tocopherol-loaded SLN suspensions measured on (A) day 1 and (B) day 7 after 
production.  
The star in A represents the particle size of the same formulation from literature (Dingler 
et al., 1999). 
 
6.4.2. Particle size characterization determined by LD 
 
Fig. 6.2 shows the LD size of the SLN® suspensions on 1 and 7 days after production. In 
consistence with the PCS results shown in Fig. 6.2, increasing the number of 
homogenization cycles reduces the particle size, and yields a narrower size distribution. 
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Both 10% tocopherol-CW-SLN after 2 or 3 homogenization cycles as well as all 
tocopherol-C-SLN suspensions show nano-range particle sizes, with narrow size 
distributions one day after production. Although the z-ave values of 10% tocopherol-CW-
SLN after 2 and 3 cycles were very similar, a wider size distribution was measured after 
2 homogenization cycles. This phenomenon is mentioned in literature as well, and is 
explained as the “two-step diminution process” in the homogenization procedure. In the 
first step, most of the lipid particles reach their maximum dispersibility fast. In the second 
step, the effect on reducing the mean size of the particles is little, but the width of the size 
distribution can be reduced further. Thus, even though the mean sizes of the lipid 
nanoparticles after 2 and 3 cycles were similar, the additional homogenization cycle 
contributes to improve the homogeneity of the lipid nanoparticle suspension, which is in 
line with literature observations (Kovačević et al., 2014).  
 
As seen in Fig. 6.2B, larger aggregates were detected in the 10% tocopherol-CW-SLN 
formulation with 2 homogenization cycles after 7 days of storage. On the contrary, the 
same suspension proved very stable after performing 3 homogenization cycles. 90% of 
the particles were less than 1 μm in diameter, and the D95 value – which is very sensitive 
to the presence of larger aggregates – shows no obvious change after 7 days of storage. 
Meanwhile, the SLN® suspensions produced with cetyl palmitate showed excellent 
physical stability after either 2 or 3 homogenization cycles. 95% of the particles in these 
two nanosuspensions were still smaller than 0.7 μm after 7 days of storage, indicating a 
good potential for topical application. It is important to note that although the storage 
timeframes investigated in this study are relatively short, in a final product the particles 
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Fig. 6.2. Particle size distributions of α-tocopherol-loaded SLN® suspensions measured 
on (A) day 1 and (B) day 7 after production. D95 means that 95% of particles are equal 
to or lower than the given value. The same applies to D10, D50 and D90. 
 
6.4.3. Particle charge (zeta potential) 
 
The zeta potential (ZP) is commonly used for predicting the stability of nanoparticle 
suspensions (Souto et al., 2004). The ZP of the SLN® suspensions was measured in both 
conductivity water (50 µS/cm) as well as in the original medium (1.8% Tego Care 450). 
The ZP determined in conductivity water represents the Stern potential, a value depicting 
the surface charge of the particles (Nernst potential). The ZP measured in the original 
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medium is a measure for the thickness of the diffuse layer. The higher the both ZP values 
are, the higher the stability of the suspension is expected to be. The reason for this is that 
particles with a higher surface charge have a stronger electrostatic repulsion between 
them. ZP values measured in original medium higher than |30 mV| indicate good physical 
stability (Müller et al., 1996). Fig. 6.3 shows the ZP values of the α-tocopherol-loaded 
SLN® suspensions. All the particles were highly negatively charged. Zeta potential values 
measured in original medium were higher than |40 mV|. However, the LD measurements 
(Fig. 6.2) show a certain degree of aggregation for 5% tocopherol-CW-SLN despite of the 
high ZP values measured. Nonetheless, the 10% tocopherol-CW-SLN formulation with 3 
homogenization cycles as well as all cetyl palmitate SLN® suspensions have both narrow 
size distributions and high ZP values. This shows that for most formulations, the ZP values 
accurately predict the physical stability. 
 
 
Fig. 6.3. Zeta potential (ZP) of α-tocopherol-loaded SLN suspensions measured in 
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6.4.4. Differential scanning calorimetry (DSC) 
 
The thermal behavior of the produced SLN® suspensions and the bulk materials were 
analyzed by DSC (Fig. 6.4 and Table 6.2). Fig. 6.4 shows the melting curves of the lipid 
nanoparticle suspensions, and of the bulk materials from 20 °C to 95 °C at a heating rate 
of 10 K/min. Table 6.2 lists the corresponding DSC parameters as well as the calculated 
recrystallization index (RI). The SLN® suspensions produced with same lipid and same 
amount of drug loading show no obvious difference in melting curves. The melting peaks 
of SLN® produced with 10% α-tocopherol shift to lower temperature compared to 5% α-
tocopherol. The same melting point depression also occurred in enthalpy values and RIs, 
indicating a less ordered structure. The reason for this is that an increasing amount of 
liquid α-tocopherol more strongly disrupts the ordered crystal lattice (Jenning et al., 2000; 
Kovacevic et al., 2011). The onset of melting temperature of all SLN® suspensions occurs 
above the human skin temperature (32 °C), indicating a potential for dermal application 
in the solid particle state.  
 
10% α-tocopherol-loaded SLN® produced with cetyl palmitate show only very weak 
melting peaks (Fig. 6.4B), and the corresponding RIs are about 5%. This indicated that 
loading 10% of α-tocopherol is not suitable for cetyl palmitate SLN®. Thus, 10% 
tocopherol-CW-SLN with 3 homogenization cycles, loaded with 10% α-tocopherol is the 
most potential formulation for practical application, and showed perfect stability over the 
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Fig. 6.4. Differential scanning calorimetry (DSC) thermograms (20-95 °C) of the pure 
lipids (carnauba wax (A) and cetyl palmitate(B)) and SLN® loaded with 5 and 10% α-
tocopherol, following 1, 2, and 3 homogenization cycles. All samples were measured at a 
heating rate of 10 K/min. 
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Table 6.2. Melting peaks, enthalpy and recrystallization indices (RI) of the SLN® 
suspensions as well as the lipids (carnauba wax and cetyl palmitate) measured by DSC. 














1 67.14 79.43 -164.13 81.1 
2 67.03 78.96 -164.43 81.3 
3 69.02 79.45 -167.27 82.7 
10% tocopherol-CW-
SLN 
1 63.11 76.01 -158.88 78.5 
2 63.89 76.27 -159.33 78.8 
3 64.06 76.37 -161.80 80.0 
cetyl palmitate - 42.19 45.04 51.97 -201.32 100 
5% tocopherol-C-SLN 
1 41.55 47.19 
 
-106.84 53.1 
2 42.74 47.33 -106.87 53.1 
3 43.17 47.12 -107.08 53.2 
10% tocopherol-C-
SLN 
1 39.34 43.70 -10.81 5.4 
2 38.06 43.51 -10.31 5.1 




Solid lipid nanoparticles loaded with the antioxidant α-tocopherol were successfully 
prepared. The lipid nanoparticle suspensions could be increased to 10% α-tocopherol, 
and the formulations showed excellent short-term stability even at these high drug 
loadings. The nanoparticle diameters remained in the nano-range with narrow 
distributions, not changing significantly from 1 day till 7 days after production. It is 
important to note that although the stability timeframe measured is relatively short, the 
shelf life is more than enough considering such lipid nanoparticles would be rapidly 
incorporated into a semisolid base such as hydrogels or creams. The melting curves 
determined by DSC showed the lipid nanoparticles will remain solid during dermal 
application.  
 
In addition, lipid nanoparticles are already on current market for dermal delivery owing to 
the ease of upscaling as well as lack of organic solvents required for production. 
Therefore, after further optimization on the selection of dermal bases, the α-tocopherol 
Solid lipid nanoparticles (SLN®) for the delivery of α-tocopherol – an efficient method for 









Alqahtani, S., Simon, L., Astete, C.E., Alayoubi, A., Sylvester, P.W., Nazzal, S., Shen, Y., 
Xu, Z., Kaddoumi, A., Sabliov, C.M., 2015. Cellular uptake, antioxidant and 
antiproliferative activity of entrapped α-tocopherol and γ-tocotrienol in poly (lactic-co-
glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-Chi). J Colloid 
Interf Sci 445, 243-251. 
Brantley, P., Elmadfa, I., Kafatos, A., Kelly, F., Manios, Y., Roxborough, H., 2000. 539 
Schuch, W.; Sheehy, PJA; Wagner, KH Vitamin E. J. Sci. Food Agric 80, 913-938. 
Brigelius-Flohe, R., Traber, M.G., 1999. Vitamin E: function and metabolism. The FASEB 
Journal 13, 1145-1155. 
de Carvalho, S.M., Noronha, C.M., Floriani, C.L., Lino, R.C., Rocha, G., Bellettini, I.C., 
Ogliari, P.J., Barreto, P.L.M., 2013. Optimization of α-tocopherol loaded solid lipid 
nanoparticles by central composite design. Industrial Crops and Products 49, 278-285. 
Ding, Y., Nielsen, K.A., Nielsen, B.P., Bøje, N.W., Müller, R.H., Pyo, S.M., 2018. Lipid-
drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral 
cavity–optimization of nicotine loading efficiency. European Journal of Pharmaceutics and 
Biopharmaceutics. 
Dingler, A., Blum, R., Niehus, H., Muller, R., Gohla, S., 1999. Solid lipid nanoparticles 
(SLNTM/LipopearlsTM) a pharmaceutical and cosmetic carrier for the application of 
vitamin E in dermal products. Journal of microencapsulation 16, 751-767. 
Fisher, G.J., Kang, S., Varani, J., Bata-Csorgo, Z., Wan, Y., Datta, S., Voorhees, J.J., 
2002. Mechanisms of photoaging and chronological skin aging. Archives of dermatology 
138, 1462-1470. 
Freitas, C., Muller, R.H., 1999. Correlation between long-term stability of solid lipid 
nanoparticles (SLN (TM)) and crystallinity of the lipid phase. European Journal of 
Pharmaceutics and Biopharmaceutics 47, 125-132. 
Solid lipid nanoparticles (SLN®) for the delivery of α-tocopherol – an efficient method for 




Fuchs, J., 1998. Potentials and limitations of the natural antioxidants RRR-alpha-
tocopherol, l-ascorbic acid and β-carotene in cutaneous photoprotection1. Free Radical 
Biology and Medicine 25, 848-873. 
Gange, R.W., Blackett, A.D., Matzinger, E.A., Sutherland, B.M., Kochevar, I.E., 1985. 
Comparative protection efficiency of UVA-and UVB-induced tans against erythema and 
formation of endonuclease-sensitive sites in DNA by UVB in human skin. Journal of 
investigative dermatology 85, 362-364. 
Jenning, V., Gohla, S.H., 2001. Encapsulation of retinoids in solid lipid nanoparticles 
(SLN). Journal of microencapsulation 18, 149-158. 
Jenning, V., Thunemann, A.F., Gohla, S.H., 2000. Characterisation of a novel solid lipid 
nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J 
Pharmaceut 199, 167-177. 
Kovacevic, A., Savic, S., Vuleta, G., Muller, R.H., Keck, C.M., 2011. Polyhydroxy 
surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, 
physical stability and particle matrix structure. Int J Pharmaceut 406, 163-172. 
Kovačević, A.B., Müller, R.H., Savić, S.D., Vuleta, G.M., Keck, C.M., 2014. Solid lipid 
nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization 
and physical stability investigation. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects 444, 15-25. 
Lucks, J., Müller, R., 1991. Medication vehicles made of solid lipid particles (solid lipid 
nanospheres SLN). EP0000605497. 
McVean, M., Liebler, D.C., 1997. Inhibition of UVB induced DNA photodamage in mouse 
epidermis by topically applied alpha-tocopherol. Carcinogenesis 18, 1617-1622. 
Müller, R.H., Hildebrand, G., Nitzsche, R., Paulke, B.-R., 1996. Zetapotential und 
Partikelladung in der Laborpraxis. PAPERBACK APV 37. 
Müller, R.H., MaÈder, K., Gohla, S., 2000. Solid lipid nanoparticles (SLN) for controlled 
drug delivery–a review of the state of the art. European journal of pharmaceutics and 
biopharmaceutics 50, 161-177. 
Musalmah, M., Nizrana, M., Fairuz, A., NoorAini, A., Azian, A., Gapor, M., Ngah, W.W., 
2005. Comparative effects of palm vitamin E and α-tocopherol on healing and wound 
tissue antioxidant enzyme levels in diabetic rats. Lipids 40, 575-580. 
Solid lipid nanoparticles (SLN®) for the delivery of α-tocopherol – an efficient method for 




Pardeike, J., Hommoss, A., Müller, R.H., 2009. Lipid nanoparticles (SLN, NLC) in 
cosmetic and pharmaceutical dermal products. Int J Pharmaceut 366, 170-184. 
Rittié, L., Fisher, G.J., 2002. UV-light-induced signal cascades and skin aging. Ageing 
Res Rev 1, 705-720. 
Sahari, M.A., Moghimi, H.R., Hadian, Z., Barzegar, M., Mohammadi, A., 2017. 
Physicochemical properties and antioxidant activity of α-tocopherol loaded 
nanoliposome’s containing DHA and EPA. Food Chem 215, 157-164. 
Schmidt, K., 1993. Durch freie Radikale verursachte Krankheiten-Ätiologie und 
Prävention. Vitamin E in der modernen Medizin. Schriftenreihe der Nordrheinischen 
Akademie für ärztliche Fort-und Weiterbildung, MKM Verlagsgesellschaft Lenggries/Obb 
8, 67-76. 
Serbinova, E., Kagan, V., Han, D., Packer, L., 1991. Free radical recycling and 
intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-
tocotrienol. Free Radical Biology and Medicine 10, 263-275. 
Sharif, H.R., Goff, H.D., Majeed, H., Liu, F., Nsor-Atindana, J., Haider, J., Liang, R., Zhong, 
F., 2017. Physicochemical stability of β-carotene and α-tocopherol enriched 
nanoemulsions: Influence of carrier oil, emulsifier and antioxidant. Colloids and Surfaces 
A: Physicochemical and Engineering Aspects 529, 550-559. 
Souto, E., Müller, R., 2008. Cosmetic features and applications of lipid nanoparticles 
(SLN®, NLC®). International Journal of Cosmetic Science 30, 157-165. 
Souto, E., Wissing, S., Barbosa, C., Müller, R., 2004. Evaluation of the physical stability 
of SLN and NLC before and after incorporation into hydrogel formulations. European 
journal of pharmaceutics and biopharmaceutics 58, 83-90. 
Teixeira, M., Severino, P., Andreani, T., Boonme, P., Santini, A., Silva, A., Souto, E., 2017. 
d-α-tocopherol nanoemulsions: Size properties, rheological behavior, surface tension, 
osmolarity and cytotoxicity. Saudi Pharmaceutical Journal 25, 231-235. 
Trombino, S., Cassano, R., Muzzalupo, R., Pingitore, A., Cione, E., Picci, N., 2009. 
Stearyl ferulate-based solid lipid nanoparticles for the encapsulation and stabilization of 
β-carotene and α-tocopherol. Colloids and Surfaces B: Biointerfaces 72, 181-187. 
Vivek, K., Reddy, H., Murthy, R.S., 2007. Investigations of the effect of the lipid matrix on 
drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid 
Solid lipid nanoparticles (SLN®) for the delivery of α-tocopherol – an efficient method for 




nanoparticles. AAPS PharmSciTech 8, 16-24. 
Wissing, S., Lippacher, A., Müller, R., 2001. Investigations on the occlusive properties of 
solid lipid nanoparticles (SLN). Journal of cosmetic science 52, 313-324. 
Wissing, S., Müller, R., 2001. A novel sunscreen system based on tocopherol acetate 
incorporated into solid lipid nanoparticles. International journal of cosmetic science 23, 
233-243. 
Zigoneanu, I.G., Astete, C.E., Sabliov, C.M., 2008. Nanoparticles with entrapped α-















1. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN®) for the delivery of nicotine 
to the oral cavity – optimization of nicotine loading efficiency. 
 
Nicotine lipid-drug-conjugates (LDC) were prepared by mixing nicotine with a fatty acid 
(Kolliwax® S or stearic acid). Hydrogenated sunflower oil (HSO) combined with the LDC 
were used as the lipid matrix in the LDC-containing SLN® system, whereas non-LDC 
SLN® were produced as a reference using HSO and pure nicotine. Both LDC-containing 
SLN® and non-LDC SLN® were successfully produced using a hot high-pressure 
homogenization method. Following production, photon correlation spectroscopy (PCS) 
confirmed all formulations were in the submicron size range (150 to 350 nm diameter) 
with narrow size distributions (PDI around 0.25). The laser diffractometry (LD) results 
showed 90% of the particles had a diameter lower than 1,000 nm. Light microscopy 
images show no aggregation of the particles, which is good agreement with the LD result. 
Differential scanning calorimetry (DSC) was used to investigate the thermal behavior of 
the system, and showed the thermal response of the four formulations was dominated by 
the HSO. The onset temperature of the melting process (> 39 °C) was higher than mouth 
temperature (37 °C), showing good applicability for buccal delivery. The nicotine-loaded 
particles could be successfully separated from the water phase using Amicon® Ultra-4 
centrifugal filter devices, and the encapsulation efficiency of nicotine in LDC-containing 
SLN® was about 50% w/w. This is an almost fivefold increase compared to the 
conventional nicotine loaded SLN® (around 10% w/w). The high degree of encapsulation 
makes the LDC-containing SLN® a promising system for buccal delivery of nicotine with 
low side effects, and incorporating the SLN® into nicotine chewing gum or lozenges has 
the potential to be an innovative nicotine replacement therapy. 
 
2. smartLipids® as third solid lipid nanoparticle generation – stabilization of retinol for 
dermal application. 
 
Following a screening of several stabilizers, Tween® 20 proved most suitable for 
smartLipids® production. smartLipids® were successfully produced by a hot high-pressure 





w/w). The mean diameter of smartLipids® formulations was about 200 nm, and remained 
unchanged during a storage period of two months as determined by PCS. DSC results 
showed an absence of polymorphic transitions, an indication of good physical stability. 
Furthermore, the onset temperatures of melting peaks were above 38 °C, ensuring the 
particles maintain their solid state during the skin penetration process (skin temperature 
is 32 °C). Results showed that after 60 days of storage, 37%, 59% and 75% w/w of retinol 
remained in the particle suspensions loaded with 5%, 15% and 20% retinol, respectively. 
Thus, the degradation of loaded retinol was reduced significantly by incorporating it into 
smartLipids® when compared to other studies. Since the loading capacity was superior to 
other studies as well, two major advantages characteristic for smartLipids® were 
combined. Dispersing the smartLipids® suspension into a gel base as a dermal 
formulation did not change the particle size, and the same chemical stability was 
observed as for the lipid nanoparticle suspension. Thus, the concept of smartLipids® 
worked efficiently for retinol, improving not only the encapsulation efficiency but also 
physical and chemical stability, as well as showing good performance in a gel base. 
 
3. The influencing factors of producing stable smartLipids®: lipids, surfactants and 
production parameters. 
 
Although smartLipids® provide a more universal delivery approach owing to the possibility 
of stabilizing a wide spectrum of different actives, the stability of the lipid nanoparticle 
suspensions strongly depends on a variety of influencing factors, and developing stable 
formulations is generally a resource- and time-intensive process. This study investigated 
in more detail the influences of the lipid compositions, the type and concentration of the 
surfactants and the production parameters on the stability. Most of the produced 
formulations instantly gelated after production, or showed macroscopic particle growth. 
The investigated lipid composition 2 and 4 - combinations of low melting range lipids - 
showed nano-ranged particle sizes, narrow particle size distributions and were stable for 
180 days. The addition of a liquid lipid increased the stability in lipid composition 2, 3 and 
4, due to the enhanced miscibility of the lipid matrix. Formulations stabilized by 





stability. On the contrary, increasing the concentration of surfactants did not successfully 
suppress aggregation when surfactants with a lower HLB value are used, likely owing to 
increased Ostwald ripening. Furthermore, the zeta potential value did not reliably predict 
the long-term stability of smartLipids®. Both stable lipid nanoparticle suspensions with low 
zeta potential were encountered as well as unstable formulations with a high zeta 
potential were encountered, showing that steric effects are important. Additionally, the 
most stable formulations were achieved by performing only 1 or 2 homogenization cycles. 
 
4. Solid lipid nanoparticles (SLN®) for the delivery of α-tocopherol – an efficient method 
for improving the drug loading capability. 
 
Solid lipid nanoparticle suspensions loaded with 5% and 10% α-tocopherol (w/w) were 
successfully developed. The mean particle sizes of these lipid nanoparticle suspensions 
remained in the nano-range following production, and their size distributions narrowed 
with an increasing number of homogenization cycles. After storing all suspensions at 
room temperature for 7 days, the SLN® suspensions produced with carnauba wax did not 
remain stable, except for the formulation produced with 10% α-tocopherol and 3 
homogenization cycles. On the contrary, all SLN® suspensions produced with cetyl 
palmitate showed great physical stability. Zeta potential values of the produced lipid 
nanoparticle suspensions measured in original medium were higher than |40 mV|, and in 
conductivity water were higher than |60 mV|, a sign of potentially good physical stability. 
The thermal analysis of SLN® suspensions showed very weak peaks in 10% α-
tocopherol-loaded SLN® produced with cetyl palmitate, indicative of an only slightly 
ordered matrix. Therefore, 10% α-tocopherol-loaded SLN® produced with carnauba wax 
and 3 homogenization cycles were recommended for further practical usage. Furthermore, 
the onset of the melting behavior of this SLN® suspension occurs above skin temperature, 
making it suitable for dermal application. Using carnauba wax and producing the 
formulation with 3 homogenization cycles, the loading of α-tocopherol could be increased 
to 10% w/w. Aside from increased drug loading, this formulation has a suitable particle 
size, narrow size distribution, good physical stability as well as a desirable thermal profile, 











1. Feste Lipid Nanopartikel (SLN) mit Lipid-Arzneistoff-Konjugat (LDC) für die Freisetzung 
von Nicotin in der Mundhöhle – Optimierung der Nicotin-Beladungseffizienz. 
 
Nicotin-Lipid-Konjugate (LDC) wurden durch eine Mischung von Nicotin und einer 
Fettsäure (Kolliwax® S bzw. Stearinsäure) hergestellt. Hydriertes Sonnenblumenkernöl 
(HSO) und das LDC wurden als Matrix für die LDC-SLN®-System verwendet. Zusätzlich 
wurden LDC-freie SLN® unter Verwendung von HSO und reinem Nicotin als Referenz 
hergestellt. Sowohl die LDC-SLN® als auch die Referenz wurden erfolgreich mittels 
Hochdruckhomogenisation hergestellt. Alle produzierten Formulierungen wiesen eine 
mittels Photonen-Korelations-Spektroskopie (PCS) bestimmte mittele Teilchengröße 
zwischen 150 und 350 nm, sowie eine enge Partikelgrößenverteilung (PDI bei etwa 0,25) 
auf. Mittels Laserdiffraktometrie (LD) wurden nachgewiesen, dass 90% aller Partikel 
einen Durchmesser < 1000 nm aufwiesen. Die Abwesenheit von Aggregaten wurde 
mittels Lichtmikroskopie nachgewiesen. Darüber hinaus wurde das thermische Verhalten 
der LDC-SLN® mittels Dynamischer Differenzkalorimetrie (DSC) bestimmt, wobei sich 
zeigte, dass das Schmelzverhalten in erster Linie durch HSO bestimmt wird. Die 
Lipidmatrix begann erst bei 39 °C zu schmelzen, was über der üblichen Temperatur in 
der Mundhöhle (37 °C) liegt und die buccale Anwendbarkeit bestätigt. Die Nicotin 
beladenen Partikel wurden mit Hilfe eines Amicon® Ultra-4 Zentrifugenfilter von der 
wässrigen Phase abgetrennt, wodurch die Einschlusseffizienz des Wirkstoffs mit etwa 50% 
(w/w) bestimmt werden konnte. Dieser Wert übersteigt die Effizienz des konventionell mit 
Nicotin beladenen SLN® (etwa 10%) um das Fünffache. Diese hohe Einschlusseffizienz 
der LDC-beladenen SLN® ist vielversprechend für die Anwendung von Nicotin in der 
Mundhöhle und zeichnet sich wahrscheinlich durch weniger Nebenwirkungen aus. 
Werden die SLN® in Kaugummi oder Lutschpastillen eingearbeitet, haben sie das 
Potential, eine innovative Nicotin-Ersatz-Therapie darzustellen. 
 
2. smartLipids® als dritte Generation der Lipidnanopartikel – Stabilisierung von Retinol 
zur dermalen Anwendung. 
 





Herstellung der smartLipids®. smartLipids® wurden mittels Hochdruckhomogenisation 
hergestellt und mit verschiedenen Konzentrationen Retinol (5%, 15%, 20% w/w) beladen. 
Der mittlere Durchmesser der smartLipids®-Formulierung betrug etwa 200 nm (PCS) und 
zeigte auch nach zwei Monaten Lagerung keine Veränderung, Mittels DSC wurde 
nachgewiesen, dass keinerlei Polymorphie auftrat, was eine gute physikalische Stabilität 
der Formulierung beweist. Darüber hinaus wurde der Onset des Schmelzens oberhalb 
von 38 °C bestimmt, so dass die Partikel während der Penetration auf der Haut im festen 
Zustand verbleiben (die Temperatur der Haut beträgt 32 °C). Die Ergebnisse zeigen, dass 
nach 60 Tagen Lagerung 37%, 59% und 75% (w/w) des Retinols in den 
Partikelsuspensionen mit 5%, 15% bzw. 20% verblieben. Demnach konnte die chemische 
Zersetzung von Retinol durch smartLipids® im Vergleich zu anderen Studien erheblich 
verringert werden. Da auch die Retinol-Beladung anderen Studien überlegen ist, 
vereinigen smartLipids® zwei charakteristische Vorteile. Darüber hinaus kann die 
smartLipids®-Suspension in eine Gelformulierung eingearbeitet werden. Die 
Partikelgröße und chemische Stabilität der Lipid Nanopartikel Suspension wurden 
dadurch nicht beeinflusst. Demnach funktioniert das smartLipids®-Konzept sehr effektiv 
für Retinol, wodurch nicht nur die Einschlusseffizienz, die physikalische und chemische 
Stabilität werden konnten, auch die Einarbeitung in ein Gel funktioniert problemlos. 
 
3. Einflussfaktoren auf die Stabilität von smartLipids®: Lipide, Tenside und 
Produktionsparameter. 
 
Obwohl smartLipids® durch die Stabilisierung eines breiten Spektrums verschiedener 
Wirkstoffe einen universellen carrier darstellen, hängt die Stabilität der Lipid Nanopartikel 
Suspensionen von einer Vielzahl von Einflussfaktoren ab. Diese Studie untersuche 
detailliert den Einfluss der Lipidkomponenten, der Art und Konzentration des Tensids und 
der Produktionsparameter auf die Stabilität. Die Mehrzahl der getesteten Formulierungen 
bildete sofort nach der Produktion ein Gel aus oder zeigte bereits makroskopisch 
Partikelwachstum. Die Untersuchten Lipidmischungen 2 und 4 – Kombinationen von 
niedrig schmelzenden Lipiden – zeigten Partikelgrößen im Nanometer-Bereich, eine enge 





Lipides verbesserte die Stabilität der Lipid-Zusammensetzungen 2, 3 und 4, was durch 
diene verbesserte Mischbarkeit der Einzelkomponenten in der Lipidmatrix erklärt werden 
kann. Formulierungen, die mit einem Tensid mit einem hohen HLB-Wert stabilisiert 
wurden, zeigten verbessere physikalische Stabilität. Im Gegensatz dazu konnte eine 
höhere Konzentration eines Tensids mit einem höheren HLB-Wert die Aggregation der 
Partikel nicht immer verhindern, wobei die Ostwald-Reifung eine Rolle spielt. Das Zeta-
Potential konnte nicht zuverlässig die Langzeitstabilität der smartLipids® voraussagen. 
Sowohl stabile Lipid Nanopartikel Suspensionen mit niedrigem Zeta-Potential als auch 
instabile Formulierungen mit hohem Zeta-Potential wurden beobachtete, da die 
Stabilisierung in erster Linie durch sterische Effekte der Tenside zustande kommt. 
Darüber hinaus wurden die stabilsten Formulierungen nach lediglich 1-2 Homogenisier-
Zyklen gefunden. 
 
4. Feste Lipid Nanopartikel (SLN®) für die Freisetzung von α-Tocopherol – eine Effiziente 
Methode zur Steigerung der Wirkstoff-Beladung. 
 
Feste Lipid Nanopartikel-Suspensionen mit 5% und 10% α-Tocopherol (w/w) wurden 
entwickelt. Die mittlere Partikelgröße dieser Suspensionen wurde im Nanometer-Bereich 
bestimmt, und die Partikelgrößenverteilung wurde mit steigender Anzahl an 
Homogenisierzyklen enger. Bei einer Lagerung bei Raumtemperatur über 7 Tage waren 
alle Karnaubawachs-haltigen SLN instabil. Die einzige Ausnahme stellte die 
Formulierung mit 10% α-Tocopherol nach 3 Homogenisierzyklen dar. Im Gegensatz dazu 
zeigten alle mit Cetylpalmitat produzierten Formulierungen ausgezeichnete physikalische 
Stabilität. Die Beträge der Zeta Potentiale aller Formulierungen waren größer als |40 mV| 
im Original-Medium und |60 mV| in Wasser. Daraus lässt sich eine gute physikalische 
Stabilität ableiten. Die thermografische Analyse zeigte sehr schwache Peaks der mit 10% 
α-Tocopherol beladenen SLN® mit Cetylpalmitat. Dies zeigt eine Matrix an, die einen 
geringen Ordnungsgrad aufweist. Aus diesem Grund wird empfohlen, die 10%-beladene 
Karnaubawachs Formulierung nach dem 3. Homogenisierzyklus zu verwenden. Der 
Schmelzpunkt dieser Formulierung liegt oberhalb der Hauttemperatur, wodurch sie 





Homogenisierzyklen konnte die Beladungskapazität von α-Tocopherol auf 10% (w/w) 
gesteigert werden. Neben der hohen Beladung zeigt die Formulierung Partikel im 
Nanometer-Bereich, eine Partikelgrößenverteilung, gute physikalische Stabilität sowie 















API active pharmaceutical ingredient 
CMC critical micelle concentrations  
DSC differential scanning calorimetry 
FDA US Food and Drug Administration 
HLB hydrophilic-lipophilic balance 
HPC hydroxypropyl cellulose 
HPLC high performance liquid chromatography 
HPH high pressure homogenization 
LD laser diffractometry 
LDC lipid-drug-conjugate 
LM light microscopy 
NLC nanostructured lipid carriers 
PCS photo correlation spectroscopy 
PDI polydispersity index 
PEG polyethylene glycol 
RI recrystallization indices 
RT room temperature 
SLN solid lipid nanoparticles 










Chapter 5. The influence of lipids, surfactants and homogenization cycles in physical 
stability of smartLipids® 
 
A. Formulations stable for 120 days. 
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B. Formulations stable for 90 days. 
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C. Formulations stable for 60 days. 
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D. stable for 30 days 
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Fig. A1. The PCS data (z-ave and PDI) and LD data (D10, D50, D90 and D95) of the 
smartLipids® suspensions with different stability properties: A. stable for 120 days, B. 
stable for 90 days, C. stable for 60 days and D. stable for 30 days. 
 DG: decyl glucoside; LG: lauryl glucoside; T: Tween® 80; P: Plantacare® 2000 UP 












Chapter 5. The influence of lipids, surfactants and homogenization cycles in physical 
stability of smartLipids® 
 
Table A1. Zeta potential (ZP) values of LM4/0 smartLipids® formulations measured in 
conductivity water (CW) and original medium (OM), correlated to respective storage 
stabilities.  
pressure [bar] homogenization cycle 
zeta potential [mV] 
storage stability [day] 
CW OM 
300 
1 -45.9 -17.8 90 
2 -43.2 -15.9 90 
3 -41.7 -15.0 90 
4 -41.9 -15.5 90 
400 
1 -45.0 -17.3 90 
2 -39.2 -13.9 90 
3 -37.9 -13.8 90 
4 -37.7 -12.8 90 
500 
1 -44.9 -16.9 < 30 
2 -39.6 -16.1 90 
3 -39.9 -13.1 90 
4 -40.8 -15.5 90 
600 
1 -42.1 -17.2 90 
2 -41.1 -13.6 90 
3 -38.4 -13.8 90 
4 -39.9 -16.8 < 30 
700 
1 -45.5 -17.9 < 30 
2 -40.5 -14.9 90 
3 -40.9 -15.0 90 








1 -47.3 -17.1 < 30 
2 -44.6 -14.8 90 
3 -42.9 -15.2 90 
4 -40.5 -15.0 90 
900 
1 -44.4 -16.0 90 
2 -43.8 -14.7 90 
3 -39.2 -15.7 < 30 
4 -41.9 -15.7 90 
1000 
1 -47.6 -19.3 < 30 
2 -44.0 -14.9 30 
3 -40.5 -14.7 < 30 
























Chapter 5. The influence of lipids, surfactants and homogenization cycles in physical 
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Fig. A2. The PCS data (z-ave and PDI) and LD data (D10, D50, D90 and D95) of the 





and 1000 bar) and homogenization cycle numbers (1, 2, 3 and 4) measured on day 1, 30 
and 90. 
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